

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(10) **DK/EP 1888643 T3**

(12) **Oversættelse af
europæisk patentskrift**

-
- (51) Int.Cl.: **C 07 K 16/24 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2015-01-05**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2014-10-29**
- (86) Europæisk ansøgning nr.: **06742970.4**
- (86) Europæisk indleveringsdag: **2006-05-17**
- (87) Den europæiske ansøgnings publiceringsdag: **2008-02-20**
- (86) International ansøgning nr.: **EP2006004696**
- (87) Internationalt publikationsnr.: **WO2006122797**
- (30) Prioritet: **2005-05-18 US 682009 P**
- (84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR**
- (73) Patenthaver: **MorphoSys AG, Lena-Christ-Strasse 48, 82152 Martinsried/München, Tyskland**
- (72) Opfinder: **THOMASSEN-WOLF, Elisabeth, Wolfgang-Krämer-Strasse 5, 82131 Gauting, Tyskland**
STEIDL, Stefan, Planegger Strasse 37, 81241 München, Tyskland
- (74) Fuldmægtig i Danmark: **Budde Schou A/S, Hausergade 3, 1128 København K, Danmark**
- (54) Benævnelse: **Anti-GM-CSF-antistoffer samt deres anvendelser**
- (56) Fremdragne publikationer:
WO-A-97/08320
WO-A2-03/068920
KREBS B ET AL: "High-throughput generation and engineering of recombinant human antibodies" JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 254, no. 1-2, 1 August 2001 (2001-08-01), pages 67-84, XP004245443 ISSN: 0022-1759
KNAPPIK A ET AL: "Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 296, no. 1, 11 February 2000 (2000-02-11), pages 57-86, XP004461525 ISSN: 0022-2836
RAUCHENBERGER ROBERT ET AL: "Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 40, 3 October 2003 (2003-10-03), pages 38194-38205, XP002404703 ISSN: 0021-9258
KRINNER EVA-MARIA ET AL: "A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF." MOLECULAR IMMUNOLOGY. FEB 2007, vol. 44, no. 5, February 2007 (2007-02), pages 916-925, XP002404704 ISSN: 0161-5890

Description**BACKGROUND OF THE INVENTION**

5 **[0001]** Granulocyte-macrophage colony stimulating factor, GM-CSF, was originally identified as a hemopoietic growth factor. It is produced by a number of cell types including lymphocytes, monocytes, endothelial cells, fibroblasts and some malignant cells (Metcalf et al., 1986; Clark and Kamen, 1987; Hart et al., 1988; Metcalf et al., 1986). In addition to having a function of growth stimulation and differentiation on hemopoietic precursor cells, GM-CSF also was discovered as having a variety of effects on cells of the immune system expressing the GM-CSF receptor (for review see: Hamilton, 10 2002; de Groot et al., 1998). The most important of these functions is the activation of monocytes, macrophages and granulocytes in several immune and inflammatory processes (Gasson et al., 1990b; Gasson et al., 1990a; Hart et al., 1988; Rapoport et al., 1992).

[0002] Mature GM-CSF is a monomeric protein of 127 amino acids with two glycosylation sites. The variable degree of glycosylation results in a molecular weight range between 14kDa and 35kDa. Non-glycosylated and glycosylated GM-CSF show similar activity in vitro (Cebon et al., 1990). The crystallographic analysis of GM-CSF revealed a barrel-shaped structure composed of four short alpha helices (Diederichs et al., 1991). The overall folding is similar to other growth factors like growth hormone, interleukin-2 and interleukin-4.

[0003] GM-CSF exerts its biological activity by binding to its receptor (Kastelein and Shanafelt, 1993; Sisson and Dinarello, 1988). The most important sites of GM-CSF receptor (GM-CSF-R) expression are on the cell surface of myeloid cells and endothelial cells, whereas lymphocytes are GM-CSF-R negative. The native receptor is composed of at least two subunits, alpha and beta. The alpha subunit imparts ligand specificity and binds GM-CSF with nanomolar affinity (Gearing et al., 1989; Gasson et al., 1986). The beta subunit is also part of the interleukin-3 and interleukin-5 receptor complexes and, in association with the GM-CSF receptor alpha subunit and GM-CSF, leads to the formation of a complex with picomolar binding affinity (Hayashida et al., 1990). The binding domains on GM-CSF for the receptor have been mapped: GM-CSF interacts with the beta subunit of its receptor via a very restricted region in the first alpha helix of GM-CSF (Shanafelt et al., 1991b; Shanafelt et al., 1991a; Lopez et al., 1991). Binding to the alpha subunit could be mapped to the third alpha helix, helix C, the initial residues of the loop joining helices C and D, and to the carboxyterminal tail of GM-CSF (Brown et al., 1994).

[0004] Formation of the GM-CSF trimeric receptor complex leads to the activation of complex signaling cascades involving molecules of the JAK/STAT families, Shc, Ras, Raf, the MAP kinases, phosphatidylinositol-3-kinase and NFkB, finally leading to transcription of c-myc, c-fos and c-jun. Activation is mainly induced by the beta subunit of the receptor (Hayashida et al., 1990; Kitamura et al., 1991; Sato et al., 1993). The shared beta subunit is also responsible for the overlapping functions exerted by IL-3, IL-5 and GM-CSF (for review see: de Groot et al., 1998).

[0005] Apart from its hemopoietic growth and differentiation stimulating activity, GM-CSF functions especially as a proinflammatory cytokine. Macrophages and monocytes as well as neutrophils and eosinophils become activated by GM-CSF, resulting in the release of other cytokines and chemokines, matrix degrading proteases, increased HLA expression and increased expression of cell adhesion molecules or receptors for CC-chemokines. The latter, in turn, leads to increased chemotaxis of inflammatory cells into inflamed tissue (Chantry et al., 1990; Hamilton, 2002; Sisson and Dinarello, 1988; Zhang et al., 1998; Hamilton et al., 1993; Lopez et al., 1986; Cheng et al., 2001; Gomez-Cambronero et al., 2003). Often, GM-CSF exerts its activity in synergy with other inflammatory stimulating factors like other cytokines or LPS, e.g. neutrophils treated with GM-CSF in combination with e.g. LPS will show increased oxidative burst (Kaufman et al., 1989; Rapoport et al., 1992).

GM-CSF as target for anti-inflammatory therapy:

45 **[0006]** Due to its diverse activating functions in the immune system, GM-CSF can be considered as a target for anti-inflammatory therapy. Chronic and acute inflammatory diseases like rheumatoid arthritis (RA), multiple sclerosis (MS), Crohn's disease, psoriasis, asthma, atopic dermatitis or shock may well benefit from the blocking of GM-CSF activity and subsequent reduction of harmful activities of GM-CSF responsive cells (Hamilton, 1993; Zhang et al., 1998; Hamilton, 50 2002).

Arthritis:

[0007] Several groups showed that GM-CSF, as well as its receptor, are present in the synovial joint of arthritis patients (Alvaro-Gracia et al., 1991; Xu et al., 1989; Haworth et al., 1991). Additionally, GM-CSF was shown to cause flares of rheumatoid arthritis in patients treated with GM-CSF for neutropenia in Felty's syndrome (Hazenberg et al., 1989) or after chemotherapy (de Vries et al., 1991).

[0008] First hints on the usefulness of antibodies blocking GM-CSF for the treatment of arthritis came from mouse in

EP 1 888 643 B1

vivo studies (Campbell et al., 1997; Campbell et al., 1998; Cook et al., 2001). Specifically, Cook et al. showed that neutralizing antibodies to GM-CSF showed efficacy in a collagen-induced arthritis model. Blocking of GM-CSF led to a reduction of disease severity concerning inflammation, cartilage destruction and progression of disease in initially affected limbs or progression to other limbs.

5 **[0009]** There are several effects of an anti-GM-CSF therapy from which the patients with rheumatoid arthritis or with other inflammatory diseases could benefit.

[0010] Blocking GM-CSF is expected to inhibit or reduce:

10 a) the activation and number of mature monocytes, macrophages, and neutrophils. Especially neutrophils and macrophages are abundant in synovial fluid and membrane. The macrophage number in the synovium has been shown to correlate with the degree of erosion in RA joints (Mulherin et al., 1996; Burmester et al., 1997). Macrophages are the source of a variety of other proinflammatory cytokines and matrix degrading proteases. Production of H₂O₂ by neutrophils is part of the destructive processes taking place in the arthritic joints (Babior, 2000).

15 b) the differentiation of myeloid dendritic cells (DCs) and activation of synovial DCs (= synoviocytes). GM-CSF upregulates and maintains HLA class II expression on DCs and RA synoviocytes (Alvaro-Gracia JM et al., 1991). DCs are instructed within the joint to acquire functions associated with the selective activation of inflammatory T-cells. Specific HLA-DR alleles have been linked to susceptibility to RA, and activation of T-cells via antigen presentation of DC's may play a crucial role in this type of immune disease (Santiago-Schwarz et al., 2001).

20 Multiple Sclerosis:

[0011] In multiple sclerosis, elevated levels of GM-CSF correlate with the active phase of MS (Carrieri et al., 1998; McQualter et al., 2001) and GM-CSF^{-/-} mice fail to develop disease in the model system for MS, experimental encephalomyelitis, EAE (McQualter et al., 2001).

25

Asthma:

30 **[0012]** In asthma, increased amounts of GM-CSF in the lung have been reported (Broide and Firestein, 1991). At the same time eosinophils are elevated, on which GM-CSF in synergy with interleukin-5 acts in three ways: i) it stimulates the differentiation from progenitor cells into eosinophils, ii) it stimulates their functional activation, and iii) it prolongs the survival of eosinophils in the lung (Broide et al., 1992; Yamashita et al., 2002). Thus, reduction of the survival of eosinophils in asthmatic airways by blocking GM-CSF is likely to ameliorate disease. The usefulness of anti-GM-CSF neutralizing antibodies was further shown in a model for murine asthma where the administration of such antibodies led to significant reduction of airway hyperresponsiveness and airway inflammation (Yamashita et al., 2002).

35 **[0013]** In a different mouse model, LPS-dependent inflammation of the lung could be reduced by application of anti-GM-CSF antibody 22E9 in the mouse (Bozinovski et al., 2003).

Toxic effects:

40 **[0014]** Mice homozygous for a disrupted granulocyte/macrophage colony-stimulating factor (GM-CSF) gene develop normally and show no major perturbation of hematopoiesis up to 12 weeks of age. While most GM-CSF-deficient mice are superficially healthy and fertile, all develop a disorganized vascular extracellular matrix with disrupted and reduced collagen bundles and abnormal lungs with impaired pulmonary surfactant clearance and reduced resistance to microbial pathogens in the lung. Features of the latter pathology resemble the human disorder pulmonary alveolar proteinosis (PAP). GM-CSF does not seem to be essential for the maintenance of normal levels of the major types of mature hematopoietic cells and their precursors in blood, marrow, and spleen. However, they implicate GM-CSF as being essential for normal vascular development, pulmonary physiology, and for resistance to local infection (Stanley et al., 1994; Dranoff et al., 1994; Plenz et al., 2003; Shibata et al., 2001). Recently, a strong association of auto-antibodies to GM-CSF with PAP has additionally implicated GM-CSF signaling abnormalities in the pathogenesis of PAP in humans. Together, these observations demonstrate that GM-CSF has a critical role in regulation of surfactant homeostasis and alveolar macrophage innate immune functions in the lung (Bonfield et al., 2002; Trapnell and Whitsett, 2002; Uchida et al., 2004; Kitamura et al., 1999).

45 **[0015]** High titers of autoantibodies with blocking activity to GM-CSF have been described in patients with myasthenia gravis. These patients did not show any other autoimmune phenomena or hemopoietic deficiencies or "other obvious clinical correlates" (Meager et al., 1999).

50 **[0016]** The compound E21R, a modified form of GM-CSF that antagonizes the function of GM-CSF, had been evaluated in a phase I safety trial and was found to have a good safety profile in cancer patients (Olver et al., 2002).

[0017] Thus, apart from the lung function, which should be monitored closely, other side effects are not expected when

applying an anti-GM-CSF therapy.

[0018] So far, only antibodies derived from non-human species with GM-CSF neutralizing function have been generated. For example, EP 0499161 A1 describes an antibody generated by immunization of mice with oligopeptides, the sequence of which is derived from a GM-CSF. Furthermore, the application discloses a method of alleviating in a mammal in need thereof an undesirable effect of GM-CSF, which comprises administering to said mammal a GM-CSF-inhibiting amount of an immunoglobulin. However, that antibody is a murine antibody, rendering it unsuitable for human administration.

[0019] Additionally, WO 03/068920 discloses a chimeric mouse/human IgG1 antibody, referred to therein as chimeric 19/2, that is reported to demonstrate neutralizing-activity of GM-CSF stimulated cell growth. Antibodies that contain non-human sequences are likely to elicit an immune response in the human patient and are not appropriate for the therapeutic administration. For instance, in diseases where long-term treatment is required (e.g. chronic inflammatory diseases like rheumatoid arthritis, asthma and multiple sclerosis), continued administration of a non-human therapeutic agent increases the likelihood of a severe inflammatory reaction and the production of human antibodies that may neutralize the therapeutic agent.

[0020] Correspondingly, in light of the great potential for anti-GM-CSF antibody therapy, there is a high need for human anti-GM-CSF antibodies with high affinity that effectively block the GM-CSF/GM-CSF receptor interaction. Additionally, it would be advantageous to have one or more antibodies that can cross-react with GM-CSF of one or more non-human species in order to test their efficacy in animal-based in vivo models.

[0021] The disclosed antibodies satisfies these and other needs by providing fully highly efficacious anti-GM-CSF antibodies, which are described below.

SUMMARY OF THE INVENTION

[0022] The invention relates to the embodiments as defined in the claims.

[0023] It is an object of the disclosure to provide human and humanized antibodies that can effectively block the GM-CSF/GM-CSF receptor interaction.

[0024] It is another object of the disclosure to provide antibodies that are safe for human administration.

[0025] It is also an object of the present disclosure to provide methods for treating disease or and/or conditions associated with the presence of GM-CSF by using one or more antibodies herein disclosed. These and other objects are more fully described herein.

[0026] In one aspect, the disclosure provides an antigen-binding region that is specific for human GM-CSF, where the isolated human or humanized antibody or functional fragment thereof is able (i) to block interaction of 0.5 $\mu\text{g/ml}$ human GM-CSF with the alpha chain of human GM-CSF receptor expressed on about 2×10^5 CHO-K1 cells by at least 50% under the following conditions: (a) the concentration of the human GM-CSF receptor alpha chain expressed on the CHO-K1 cells is similar to the concentration of human GM-CSF receptor alpha chain expressed on about 2×10^5 CHO-GMRa#11 cells, and (b) the concentration of the isolated human or humanized antibody or functional fragment thereof is about 5 $\mu\text{g/ml}$; and (ii) to neutralize 0.25 ng/ml human GM-CSF in a TF-1 proliferation assay with an at least five-fold lower IC_{50} value than reference antibody BVD2-21C11 and/or reference antibody MAB215. As used herein, a "TF-1 proliferation assay" is defined as the assay essentially as described in Example 5B. The skilled worker can obtain CHO-K1 cells expressing human GM-CSF receptor alpha chain at a concentration similar to that which is expressed on about 2×10^5 CHO-GMRa#11 cells by following the teachings provided herein.

[0027] The disclosure additionally provides an isolated human or humanized antibody or functional antibody fragment that contains an antigen-binding region as disclosed herein. Such an antibody or functional fragment thereof may contain an antigen-binding region that contains an H-CDR3 region depicted in SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 51 or 52; the antigen-binding region may further include an H-CDR2 region depicted in SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 51 or 52; and the antigen-binding region also may contain an H-CDR1 region depicted in SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 51 or 52. Such an antibody or functional fragment thereof may contain an antigen-binding region that contains a variable heavy chain depicted in SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 51 or 52. Such a GM-CSF-specific antibody may contain an antigen-binding region that contains an L-CDR3 region depicted in SEQ ID NO: 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61; the antigen-binding region may further include an L-CDR2 region depicted in SEQ ID NO: 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61; and the antigen-binding region also may contain an L-CDR1 region depicted in SEQ ID NO: 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61. Such an antibody or functional fragment thereof may contain an antigen-binding region that contains a variable light chain depicted in SEQ ID NO: 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61.

[0028] Peptide variants of the sequences disclosed herein are also embraced by the present disclosure. Accordingly, the disclosure includes anti-GM-CSF antibodies having a heavy chain amino acid sequence with: at least 60 percent sequence identity in the CDR regions with the CDR regions depicted in SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19,

EP 1 888 643 B1

20, 49, 50, 51 or 52; and or at least 80 percent sequence homology in the CDR regions with the CDR regions depicted in SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 49, 50, 51 or 52. Further included are anti-GM-CSF antibodies having a light chain amino acid sequence with: at least 60 percent sequence identity in the CDR regions with the CDR regions depicted in SEQ ID NO: 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61; and or at least 80 percent sequence homology in the CDR regions with the CDR regions depicted in SEQ ID NO: 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 58, 59, 60 or 61.

[0029] An antibody of the disclosure may be an IgG (e.g., IgG₁), while an antibody fragment may be a Fab or scFv, for example. An antibody fragment, accordingly, may be, or may contain, an antigen-binding region that behaves in one or more ways as described herein.

[0030] The disclosure also is related to isolated nucleic acid sequences, each of which can encode an antigen-binding region of a human or humanized antibody or a functional antibody fragment that is specific for GM-CSF. Such a nucleic acid sequence may encode a variable heavy chain of an isolated human or humanized antibody or functional fragment thereof comprising SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 44, 45, 46, 47 or 48, or a nucleic acid sequence that hybridizes under high stringency conditions to the complementary strand of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 44, 45, 46, 47 or 48. The nucleic acid might encode a variable light chain of an isolated human or humanized antibody or functional fragment thereof comprising SEQ ID NO: 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 53, 54, 55, 56 or 57, or a nucleic acid sequence that hybridizes under high stringency conditions to the complementary strand of SEQ ID NO: 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 53, 54, 55, 56 or 57.

[0031] The nucleic acid sequence might encode an antigen-binding region of a human or humanized antibody or a functional antibody fragment that is specific for human GM-CSF, where the antibody or functional fragment thereof is able (i) to block interaction of 0.5 µg/ml human GM-CSF with the alpha chain of human GM-CSF receptor expressed on 2x10⁵ CHO-K1 cells by at least 50% under the following conditions: (a) the concentration of said human GM-CSF receptor alpha chain expressed on said CHO-K1 cells is similar to the concentration of human GM-CSF receptor alpha chain expressed on 2x10⁵ CHO-GMRa#11 cells and (b) the concentration of said isolated human or humanized antibody or functional fragment thereof is about 5µg/ml, and (ii) to neutralize 0.25 ng/ml human GM-CSF in a TF-1 proliferation assay with an at least five-fold lower IC₅₀ value than the reference antibody BVD2-21C11 and/or reference antibody MAB215.

[0032] Nucleic acids of the disclosure are suitable for recombinant production. Thus, the disclosure also relates to vectors and host cells containing a nucleic acid sequence

[0033] Such host cells might be bacterial or eukaryotic cells.

[0034] Compositions of the disclosure may be used for therapeutic or prophylactic applications. The disclosure, therefore, includes a pharmaceutical composition containing an antibody (or functional antibody fragment) and a pharmaceutically acceptable carrier or excipient therefor. In a related aspect, the disclosure provides a method for treating a disorder or condition associated with the undesired presence of GM-CSF or GM-CSF expressing cells. Such method contains the steps of administering to a subject in need thereof an effective amount of the pharmaceutical composition that contains an antibody as described or contemplated herein. Such a disorder or condition might be an inflammatory disease, such as rheumatoid arthritis, multiple sclerosis, Crohn's disease, psoriasis, asthma, atopic dermatitis and shock.

[0035] Human or humanized antibodies (and functional fragments thereof) of the present disclosure may be cross-reactive with rat and/or rhesus (macaca) GM-CSF, as determined, by solution equilibrium titration (SET), and/or TF1 proliferation assay.

BRIEF DESCRIPTION OF THE FIGURES

[0036]

Figure 1a provides nucleic acid sequences of various novel antibody variable heavy chain regions.

Figure 1b provides amino acid sequences of various novel antibody variable heavy chain regions. CDR regions HCDR1, HCDR2 and HCDR3 are designated from N- to C-terminus in boldface.

Figure 2a provides nucleic acid sequences of various novel antibody variable light chain regions.

Figure 2b provides amino acid sequences of various novel antibody variable light chain regions. CDR regions LCDR1, LCDR2 and LCDR3 are designated from N- to C-terminus in boldface.

Figure 3 provides amino acid sequences of variable heavy chain regions of consensus-based HuCAL[®] antibody master gene sequences. CDR regions HCDR1, HCDR2 and HCDR3 are designated from N- to C-terminus in

boldface (SEQ ID NO: 41).

Figure 4 provides amino acid sequences of variable light chain regions of consensus-based HuCAL[®] antibody master gene sequences. CDR regions LCDR1, LCDR2 and LCDR3 are designated from N- to C-terminus in boldface (SEQ ID NO: 42).

Figure 5 provides an example of a DNA sequence of pMORPH[®]X9_MOR03929_FH expression vector (SEQ ID NO: 43).

Figure 6 provides expression level of GM-CSF receptor alpha, as determined by FACS analysis using the GM-CSF receptor alpha specific antibody MAB1006. CHO-GMRa#11 (solid line) is shown in comparison to CHO-K1 (dotted line). The x-axis represents the relative fluorescence value (RFL), measured in FL2 channel; the y-axis represents cell count.

DETAILED DESCRIPTION OF THE INVENTION

[0037] The present disclosure is based on the discovery of novel antibodies that are specific to or have a high affinity for GM-CSF and possess one or more other novel properties. Preferably, an antibody of the disclosure can deliver a therapeutic benefit to a subject. The antibodies of the disclosure, which may be human or humanized, can be used in many contexts, which are more fully described herein.

[0038] A "human" antibody or functional human antibody fragment is hereby defined as one that is not chimeric (*e.g.*, not "humanized") and not from (either in whole or in part) a non-human species. A human antibody or functional antibody fragment can be derived from a human or can be a synthetic human antibody. A "synthetic human antibody" is defined herein as an antibody having a sequence derived, in whole or in part, *in silico* from synthetic sequences that are based on the analysis of known human antibody sequences. *In silico* design of a human antibody sequence or fragment thereof can be achieved, for example, by analyzing a database of human antibody or antibody fragment sequences and devising a polypeptide sequence utilizing the data obtained therefrom. Another example of a human antibody or functional antibody fragment is one that is encoded by a nucleic acid isolated from a library of antibody sequences of human origin (*i.e.*, such library being based on antibodies taken from a human natural source).

[0039] A "humanized antibody" or functional humanized antibody fragment is defined herein as one that is (i) derived from a non-human source (*e.g.*, a transgenic mouse which bears a heterologous immune system), which antibody is based on a human germline sequence; or (ii) chimeric, wherein the variable domain is derived from a non-human origin and the constant domain is derived from a human origin or (iii) CDR-grafted, wherein the CDRs of the variable domain are from a non-human origin, while one or more frameworks of the variable domain are of human origin and the constant domain (if any) is of human origin.

[0040] As used herein, an antibody "binds specifically to," is "specific to/for" or "specifically recognizes" an antigen (here, GM-CSF) if such antibody is able to discriminate between such antigen and one or more reference antigen(s), since binding specificity is not an absolute, but a relative property. In its most general form (and when no defined reference is mentioned), "specific binding" is referring to the ability of the antibody to discriminate between the antigen of interest and an unrelated antigen, as determined, for example, in accordance with one of the following methods. Such methods comprise, but are not limited to Western blots, ELISA-, RIA-, ECL-, IRMA-tests and peptide scans. For example, a standard ELISA assay can be carried out. The scoring may be carried out by standard color development (*e.g.* secondary antibody with horseradish peroxidase and tetramethyl benzidine with hydrogenperoxide). The reaction in certain wells is scored by the optical density, for example, at 450 nm. Typical background (=negative reaction) may be 0.1 OD; typical positive reaction may be 1 OD. This means the difference positive/negative can be more than 10-fold. Typically, determination of binding specificity is performed by using not a single reference antigen, but a set of about three to five unrelated antigens, such as milk powder, BSA, transferrin or the like.

[0041] However, "specific binding" also may refer to the ability of an antibody to discriminate between the target antigen and one or more closely related antigen(s), which are used as reference points, *e.g.* between GM-CSF and IL3, IL5, IL-4, IL13 or M-CSF. Additionally, "specific binding" may relate to the ability of an antibody to discriminate between different parts of its target antigen, *e.g.* different domains or regions of GM-CSF, or between one or more key amino acid residues or stretches of amino acid residues of GM-CSF.

[0042] Also, as used herein, an "immunoglobulin" (Ig) hereby is defined as a protein belonging to the class IgG, IgM, IgE, IgA, or IgD (or any subclass thereof), and includes all conventionally known antibodies and functional fragments thereof. A "functional fragment" of an antibody/immunoglobulin hereby is defined as a fragment of an antibody/immunoglobulin (*e.g.*, a variable region of an IgG) that retains the antigen-binding region. An "antigen-binding region" of an antibody typically is found in one or more hypervariable region(s) of an antibody, *i.e.*, the CDR-1, -2, and/or -3 regions; however, the variable "framework" regions can also play an important role in antigen binding, such as by providing a

scaffold for the CDRs. Preferably, the "antigen-binding region" comprises at least amino acid residues 4 to 103 of the variable light (VL) chain and 5 to 109 of the variable heavy (VH) chain, more preferably amino acid residues 3 to 107 of VL and 4 to 111 of VH, and particularly preferred are the complete VL and VH chains (amino acid positions 1 to 109 of VL and 1 to 113 of VH; numbering according to WO 97/08320). A preferred class of immunoglobulins for use in the present disclosure is IgG. "Functional fragments" include the domain of a F(ab')₂ fragment, a Fab fragment, scFv or constructs comprising single immunoglobulin variable domains or single domain antibody polypeptides, e.g. single heavy chain variable domains or single light chain variable domains. The F(ab')₂ or Fab may be engineered to minimize or completely remove the intermolecular disulphide interactions that occur between the C_{H1} and C_L domains.

[0043] An antibody of the disclosure may be derived from a recombinant antibody library that is based on amino acid sequences that have been designed *in silico* and encoded by nucleic acids that are synthetically created. *In silico* design of an antibody sequence is achieved, for example, by analyzing a database of human sequences and devising a polypeptide sequence utilizing the data obtained therefrom. Methods for designing and obtaining *in silico*-created sequences are described, for example, in Knappik et al., J. Mol. Biol. (2000) 296:57; Krebs et al., J. Immunol. Methods. (2001) 254:67; and U.S. Patent No. 6,300,064 issued to Knappik et al..

Antibodies of the Invention

[0044] Throughout this document, reference is made to the following representative antibodies: "antibody nos." or "MOR" 03684, 04251, 03929, 04252, 04287, 04290, 04302, 04350, 04354, 04357, 03682, 04283, 04297 and 04342. MOR03684 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 1 (DNA)/SEQ ID NO: 11 (protein) and a variable light region corresponding to SEQ ID NO: 21 (DNA)/SEQ ID NO: 31 (protein). MOR04251 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 2 (DNA)/SEQ ID NO: 12 (protein) and a variable light region corresponding to SEQ ID NO: 22 (DNA)/SEQ ID NO: 32 (protein). MOR03929 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 3 (DNA)/SEQ ID NO: 13 (protein) and a variable light region corresponding to SEQ ID NO: 23 (DNA)/SEQ ID NO: 33 (protein). MOR04252 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 4 (DNA)/SEQ ID NO: 14 (protein) and a variable light region corresponding to SEQ ID NO: 24

[0045] (DNA)/SEQ ID NO: 34 (protein). MOR04287 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 5 (DNA)/SEQ ID NO: 15 (protein) and a variable light region corresponding to SEQ ID NO: 25 (DNA)/SEQ ID NO: 35 (protein). MOR04290 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 6 (DNA)/SEQ ID NO: 16 (protein) and a variable light region corresponding to SEQ ID NO: 26 (DNA)/SEQ ID NO: 36 (protein). MOR04302 represents an antibody having a variable heavy region corresponding to SEQ. ID NO: 7 (DNA)/SEQ ID NO: 17 (protein) and a variable light region corresponding to SEQ ID NO: 27 (DNA)/SEQ ID NO: 37 (protein). MOR04350 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 8 (DNA)/SEQ ID NO: 18 (protein) and a variable light region corresponding to SEQ ID NO: 28 (DNA)/SEQ ID NO: 38 (protein). MOR04354 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 9 (DNA)/SEQ ID NO: 19 (protein) and a variable light region corresponding to SEQ ID NO: 29 (DNA)/SEQ ID NO: 39 (protein). MOR04357 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 10 or 48 (DNA)/SEQ ID NO: 20 (protein) and a variable light region corresponding to SEQ ID NO: 30 or 57 (DNA)/SEQ ID NO: 40 (protein). MOR03682 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 44 (DNA)/SEQ ID NO: 49 (protein) and a variable light region corresponding to SEQ ID NO: 53 (DNA)/SEQ ID NO: 58 (protein). MOR04283 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 45 (DNA)/SEQ ID NO: 50 (protein) and a variable light region corresponding to SEQ ID NO: 54 (DNA)/SEQ ID NO: 59 (protein). MOR04297 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 46 (DNA)/SEQ ID NO: 51 (protein) and a variable light region corresponding to SEQ ID NO: 55 (DNA)/SEQ ID NO: 60 (protein). MOR04342 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 47 (DNA)/SEQ ID NO: 52 (protein) and a variable light region corresponding to SEQ ID NO: 56 (DNA)/SEQ ID NO: 61 (protein).

[0046] In one aspect, the disclosure provides antibodies having an antigen-binding region that can bind specifically to or has a high affinity for GM-CSF. An antibody is said to have a "high affinity" for an antigen if the affinity measurement is at least 100 nM (monovalent affinity of Fab fragment). An antibody or antigen-binding region preferably can bind to GM-CSF with an affinity of about less than 100 nM, more preferably less than about 60 nM, and still more preferably less than about 30 nM. Further preferred are antibodies that bind to GM-CSF with an affinity of less than about 10 nM, and more preferably less than about 3 nM. For instance, the affinity of an antibody herein disclosed against GM-CSF may be about 10.0 nM or 1 pM (monovalent affinity of Fab fragment).

[0047] Table 1 provides a summary of affinities of representative antibodies as determined by surface plasmon resonance (Biacore) and Solution Equilibrium Titration (SET) analysis:

EP 1 888 643 B1

Table 1: Antibody Affinities

	Biacore		SET
MOR0	K _D (pM)	K _D (pM)	K _D (pM)
3684	6420	16000	
4251	70	7.4	
3929	4260	2000	
4302	174	63.5	
4287	nd	17.9	
4252	55	6	
4290	122	11.1	
4350	19	1.1	
4354	21	2.8	
4357	7	0.4	
3682	nd	11406	
4283	nd	113	
4297	nd	49.2	
4342	nd	4.9	
"nd": not determined			

[0048] With reference to Table 1, the affinity of MOR03684, 04251, 03929, 04252, 04357, 04290, 04302, 04350 and 04354 was measured by surface plasmon resonance (Biacore) on immobilized recombinant GM-CSF. The Fab format of MOR03684, 04251, 03929, 04252, 04357, 04290, 04302, 04350 and 04354 exhibit a monovalent affinity range between about 6420 and 7 pM.

[0049] The Fab format was also used for the determination of the affinities by solution equilibrium titration (SET). The right column of Table 1 denotes the binding strength of between about 16000 and 0.4 pM of the MORs in this method.

[0050] An antibody of the disclosure preferably is species cross-reactive with humans and at least one other species, which may be a rodent species or a non-human primate. The non-human primate can be rhesus. The rodent species can be rat. An antibody that is cross reactive with at least one rodent species, for example, can provide greater flexibility and benefits over known anti-GM-CSF antibodies, for purposes of conducting *in vivo* studies in multiple species with the same antibody.

[0051] Preferably, an antibody of the disclosure not only is able to bind to GM-CSF, but also is able to block the interaction of human GM-CSF with the alpha chain of human GM-CSF receptor expressed on CHO-K1 cells by at least 25%, preferably by at least 50%, more preferably by at least 60%, more preferably by at least 70%, preferably by at least 85% and most preferably by at least 100%. In a preferred embodiment, an antibody herein disclosed is able to block interaction of 0.5 μg/ml human GM-CSF with the alpha chain of human GM-CSF receptor expressed on about 2x10⁵ CHO-K1 cells by at least 50% under the following conditions: the concentration of the human GM-CSF receptor alpha chain expressed on the CHO-K1 cells is similar to the concentration of human GM-CSF receptor alpha chain expressed on about 2x10⁵ CHO-GMRa#11 cells, and the concentration of the antibody is about 5μg/ml.

[0052] In this regard, the skilled worker can obtain CHO-K1 cells expressing human GM-CSF receptor alpha at a concentration similar to that which is expressed on about 2x10⁵ CHO-GMRa#11 cells by, e.g., by transfecting a population of CHO-K1 cells with a suitable expression vector encoding GM-CSF receptor alpha to generate different stable cell lines expressing defined levels GM-CSF receptor alpha; then, the stable cell lines are analyzed in FACS analysis to determine GM-CSF receptor alpha expression levels according to the protocol essentially as described in Example 3C; a cell line that expresses human GM-CSF receptor alpha at a concentration similar to that which is expressed on about 2x10⁵ CHO-GMRa#11 cells is identified by comparing the median fluorescence value (MFL) of such transfected cells to the MFL value set forth in Example 3C. As used herein, a cell line is defined as expressing GM-CSF receptor alpha at a concentration "similar" to that which is expressed on about 2x10⁵ CHO-GMRa#11 cells" if the MFL value of the transfected cell line does not deviate by more than a two-fold factor from the MFL value for the CHO-GMRa#11 cell as set forth in Example 3C.

[0053] Furthermore, an antibody of the disclosure is able to neutralize human GM-CSF in a TF-1 proliferation assay with a lower IC₅₀ value than the reference antibody BVD2-21C11 and/or MAB215, preferably an at least five-fold lower IC₅₀ value, more preferably with an at least 10-fold lower IC₅₀ value than the reference antibody BVD2-21C11 and/or MAB215, more preferably with an at least 15-fold lower IC₅₀ value than the reference antibody BVD2-21C11 and/or

MAB215, more preferably with an at least 20-fold lower IC_{50} value than the reference antibody BVD2-21C11 and/or MAB215, more preferably with an at least 30-fold lower IC_{50} value than the reference antibody BVD2-21C11 and/or MAB215, more preferably with an at least 50-fold lower IC_{50} value than the reference antibody BVD2-21C11 and/or MAB215, more preferably with an at least 100-fold lower IC_{50} value than the reference antibody BVD2-21C11 and/or MAB215 and most preferably with an at least 120-fold lower IC_{50} value than the reference antibody BVD2-21C11 and/or MAB215.

Peptide Variants

10 **[0054]** Antibodies of the disclosure are not limited to the specific peptide sequences provided herein. Rather, the disclosure also embodies variants of these polypeptides. With reference to the instant disclosure and conventionally available technologies and references, the skilled worker will be able to prepare, test and utilize functional variants of the antibodies disclosed herein, while appreciating that variants having the ability to block the interaction of GM-CSF to the alpha chain of the GM-CSF receptor fall within the scope of the present disclosure. As used in this context, "ability to block the interaction of GM-CSF to the alpha chain of the GM-CSF receptor" means a functional characteristic ascribed to an anti-GM-CSF antibody of the disclosure.

15 **[0055]** A variant can include, for example, an antibody that has at least one altered complementarity determining region (CDR) (hyper-variable) and/or framework (FR) (variable) domain/position, vis-à-vis a peptide sequence disclosed herein. To better illustrate this concept, a brief description of antibody structure follows.

20 **[0056]** An antibody is composed of two peptide chains, each containing one (light chain) or three (heavy chain) constant domains and a variable region (VL, VH), the latter of which is in each case made up of four FR regions and three interspaced CDRs. The antigen-binding site is formed by one or more CDRs, yet the FR regions provide the structural framework for the CDRs and can also play an important role in antigen binding. By altering one or more amino acid residues in a CDR or FR region, the skilled worker routinely can generate mutated or diversified antibody sequences, which can be screened against the antigen, for new or improved properties, for example.

25 **[0057]** Tables 2a (VH) and 2b (VL) delineate the CDR and FR regions for certain antibodies of the disclosure and compare amino acids at a given position to each other and to corresponding consensus or "master gene" sequences (as described in U.S. Patent No. 6,300,064):

30

35

40

45

50

55

Table 2a: VH Sequences

5
10
15
20
25
30
35
40
45
50
55

VH sequences GM-CSF binders

VH	Fragment 1										Fragment 2										Fragment 3																																																																				
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40																																																	
180-01	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S	W	V	R	Q	A	P	G	K	L	E	W	V	S	L	R	L	S	C	A	S	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S						
180-11	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S	W	V	R	Q	A	P	G	K	L	E	W	V	S	L	R	L	S	C	A	S	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S						
180-21	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S	W	V	R	Q	A	P	G	K	L	E	W	V	S	L	R	L	S	C	A	S	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S						
180-31	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S	W	V	R	Q	A	P	G	K	L	E	W	V	S	L	R	L	S	C	A	S	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S						
180-41	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S	W	V	R	Q	A	P	G	K	L	E	W	V	S	L	R	L	S	C	A	S	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S						
180-51	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S	W	V	R	Q	A	P	G	K	L	E	W	V	S	L	R	L	S	C	A	S	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S						
180-61	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S	W	V	R	Q	A	P	G	K	L	E	W	V	S	L	R	L	S	C	A	S	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S						
180-71	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S	W	V	R	Q	A	P	G	K	L	E	W	V	S	L	R	L	S	C	A	S	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S						
180-81	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S	W	V	R	Q	A	P	G	K	L	E	W	V	S	L	R	L	S	C	A	S	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S						
180-91	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S	W	V	R	Q	A	P	G	K	L	E	W	V	S	L	R	L	S	C	A	S	Q	V	L	V	S	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	S						
180-02	Q	V	R	L	V	S	G	A	E	V	K	E	P	G	S	V	K	V	S	C	K	A	S	Q	V	R	L	V	S	G	A	E	V	K	E	P	G	S	V	K	V	S	C	K	A	S	W	V	R	Q	A	P	G	K	L	E	W	V	S	L	R	L	S	C	A	S	Q	V	R	L	V	S	G	A	E	V	K	E	P	G	S	V	K	V	S	C	K	A	S
180-03	Q	V	R	L	V	S	G	A	E	V	K	E	P	G	S	V	K	V	S	C	K	A	S	Q	V	R	L	V	S	G	A	E	V	K	E	P	G	S	V	K	V	S	C	K	A	S	W	V	R	Q	A	P	G	K	L	E	W	V	S	L	R	L	S	C	A	S	Q	V	R	L	V	S	G	A	E	V	K	E	P	G	S	V	K	V	S	C	K	A	S
180-04	Q	V	R	L	V	S	G	A	E	V	K	E	P	G	S	V	K	V	S	C	K	A	S	Q	V	R	L	V	S	G	A	E	V	K	E	P	G	S	V	K	V	S	C	K	A	S	W	V	R	Q	A	P	G	K	L	E	W	V	S	L	R	L	S	C	A	S	Q	V	R	L	V	S	G	A	E	V	K	E	P	G	S	V	K	V	S	C	K	A	S
180-05	Q	V	R	L	V	S	G	A	E	V	K	E	P	G	S	V	K	V	S	C	K	A	S	Q	V	R	L	V	S	G	A	E	V	K	E	P	G	S	V	K	V	S	C	K	A	S	W	V	R	Q	A	P	G	K	L	E	W	V	S	L	R	L	S	C	A	S	Q	V	R	L	V	S	G	A	E	V	K	E	P	G	S	V	K	V	S	C	K	A	S
180-06	Q	V	R	L	V	S	G	A	E	V	K	E	P	G	S	V	K	V	S	C	K	A	S	Q	V	R	L	V	S	G	A	E	V	K	E	P	G	S	V	K	V	S	C	K	A	S	W	V	R	Q	A	P	G	K	L	E	W	V	S	L	R	L	S	C	A	S	Q	V	R	L	V	S	G	A	E	V	K	E	P	G	S	V	K	V	S	C	K	A	S
180-07	Q	V	R	L	V	S	G	A	E	V	K	E	P	G	S	V	K	V	S	C	K	A	S	Q	V	R	L	V	S	G	A	E	V	K	E	P	G	S	V	K	V	S	C	K	A	S	W	V	R	Q	A	P	G	K	L	E	W	V	S	L	R	L	S	C	A	S	Q	V	R	L	V	S	G	A	E	V	K	E	P	G	S	V	K	V	S	C	K	A	S

Table 2a continued:

5
10
15
20
25
30
35
40
45
50
55

Position	Framework 3										Framework 4																															
	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26																						
ID NO 41	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS
ID NO 11	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS
ID NO 12	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS
ID NO 13	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS
ID NO 17	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS
ID NO 16	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS
ID NO 19	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS
ID NO 15	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS
ID NO 18	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS
ID NO 14	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS
ID NO 20	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS
ID NO 62	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS
ID NO 49	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS
ID NO 51	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS
ID NO 50	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS
ID NO 52	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS	VS	RD	MS	KN	TL	YL	LQ	MM	SL	RA	ED	TA	VY	YCA	RR	WG	QG	GL	TL	VT	VS

Table 2b: VL Sequences

5
10
15
20
25
30
35
40
45
50
55

VL	VL sequences GM-CSF binders																					
	Framework 2																					
Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17					
1D140-43	D	E	L	T	Q	P	P	S	V	S	V	A	P	G	Q	T	A	R	I	S	C	
1D140-71	D	E	L	T	Q	P	P	S	V	S	V	A	P	G	Q	T	A	R	I	S	C	
1D140-20	D	E	L	T	Q	P	P	S	V	S	V	A	P	G	Q	T	A	R	I	S	C	
1D140-28	D	E	L	T	Q	P	P	S	V	S	V	A	P	G	Q	T	A	R	I	S	C	
1D140-36	D	E	L	T	Q	P	P	S	V	S	V	A	P	G	Q	T	A	R	I	S	C	
1D140-25	D	E	L	T	Q	P	P	S	V	S	V	A	P	G	Q	T	A	R	I	S	C	
1D140-34	D	E	L	T	Q	P	P	S	V	S	V	A	P	G	Q	T	A	R	I	S	C	
1D140-77	D	E	L	T	Q	P	P	S	V	S	V	A	P	G	Q	T	A	R	I	S	C	
1D140-38	D	E	L	T	Q	P	P	S	V	S	V	A	P	G	Q	T	A	R	I	S	C	
1D140-39	D	E	L	T	Q	P	P	S	V	S	V	A	P	G	Q	T	A	R	I	S	C	
1D140-40	D	E	L	T	Q	P	P	S	V	S	V	A	P	G	Q	T	A	R	I	S	C	
1D140-83	D	I	O	M	T	O	S	P	S	L	S	A	S	V	O	D	R	V	T	I	T	C
1D140-88	D	I	O	M	T	O	S	P	S	L	S	A	S	V	O	D	R	V	T	I	T	C
1D140-89	D	I	O	M	T	O	S	P	S	L	S	A	S	V	O	D	R	V	T	I	T	C
1D140-60	D	I	O	M	T	O	S	P	S	L	S	A	S	V	O	D	R	V	T	I	T	C
1D140-81	D	I	O	M	T	O	S	P	S	L	S	A	S	V	O	D	R	V	T	I	T	C

Table 2b continued:

5
10
15
20
25
30
35
40
45
50

VL	Position	Framework 3										Framework 4																																		
		BamHI		EcoRI		SmaI		XbaI		HindIII		KpnI		NotI		PstI		SalI		XhoI																										
ID NO 42	VL33	I	P	E	R	F	S	G	S	N	S	G	N	T	A	L	T	I	S	G	T	Q	A	E	D	E	A	D	Y	Y	C	V	F	G	G	T	K	L	T	V	L	G	Q			
ID NO 31	3694	I	P	E	R	F	S	G	S	N	S	G	N	T	A	L	T	I	S	G	T	Q	A	E	D	E	A	D	Y	Y	C	V	F	G	G	T	K	L	T	V	L	G	Q			
ID NO 32	4251	I	P	E	R	F	S	G	S	N	S	G	N	T	A	L	T	I	S	G	T	Q	A	E	D	E	A	D	Y	Y	C	V	F	G	G	T	K	L	T	V	L	G	Q			
ID NO 23	3929	I	P	E	R	F	S	G	S	N	S	G	N	T	A	L	T	I	S	G	T	Q	A	E	D	E	A	D	Y	Y	C	V	F	G	G	T	K	L	T	V	L	G	Q			
ID NO 36	4290	I	P	E	R	F	S	G	S	N	S	G	N	T	A	L	T	I	S	G	T	Q	A	E	D	E	A	D	Y	Y	C	V	F	G	G	T	K	L	T	V	L	G	Q			
ID NO 33	4287	I	P	E	R	F	S	G	S	N	S	G	N	T	A	L	T	I	S	G	T	Q	A	E	D	E	A	D	Y	Y	C	V	F	G	G	T	K	L	T	V	L	G	Q			
ID NO 34	4351	I	P	E	R	F	S	G	S	N	S	G	N	T	A	L	T	I	S	G	T	Q	A	E	D	E	A	D	Y	Y	C	V	F	G	G	T	K	L	T	V	L	G	Q			
ID NO 37	4302	I	P	E	R	F	S	G	S	N	S	G	N	T	A	L	T	I	S	G	T	Q	A	E	D	E	A	D	Y	Y	C	V	F	G	G	T	K	L	T	V	L	G	Q			
ID NO 38	4350	I	P	E	R	F	S	G	S	N	S	G	N	T	A	L	T	I	S	G	T	Q	A	E	D	E	A	D	Y	Y	C	V	F	G	G	T	K	L	T	V	L	G	Q			
ID NO 39	4354	I	P	E	R	F	S	G	S	N	S	G	N	T	A	L	T	I	S	G	T	Q	A	E	D	E	A	D	Y	Y	C	V	F	G	G	T	K	L	T	V	L	G	Q			
ID NO 40	4357	I	P	E	R	F	S	G	S	N	S	G	N	T	A	L	T	I	S	G	T	Q	A	E	D	E	A	D	Y	Y	C	V	F	G	G	T	K	L	T	V	L	G	Q			
ID NO 63	VL41	V	P	S	R	F	S	G	S	G	S	N	S	G	N	T	A	L	T	I	S	G	L	O	P	E	D	F	A	W	Y	Y	C	T	F	G	O	G	T	K	V	E	I	K	R	T
ID NO 58	3683	V	P	S	R	F	S	G	S	G	S	N	S	G	N	T	A	L	T	I	S	G	L	O	P	E	D	F	A	V	Y	Y	C	T	F	G	O	G	T	K	V	E	I	K	R	T
ID NO 59	4283	V	P	S	R	F	S	G	S	G	S	N	S	G	N	T	A	L	T	I	S	G	L	O	P	E	D	F	A	V	Y	Y	C	T	F	G	O	G	T	K	V	E	I	K	R	T
ID NO 60	4297	V	P	S	R	F	S	G	S	G	S	N	S	G	N	T	A	L	T	I	S	G	L	O	P	E	D	F	A	T	Y	Y	C	T	F	G	O	G	T	K	V	E	I	K	R	T
ID NO 61	4342	V	P	S	R	F	S	G	S	G	S	N	S	G	N	T	A	L	T	I	S	G	L	O	P	E	D	F	A	T	Y	Y	C	T	F	G	O	G	T	K	V	E	I	K	R	T

[0058] The original HuCAL® master genes have been constructed with their authentic N-termini, e.g. VL lambda 3 contains the amino acids "SY" at position 1 and 2; and VH3 contains the amino acid "E" at position 1. During construction of the HuCAL® Fab libraries, including the HuCAL GOLD® library, the first two amino acids have been changed to "DI" in the VL lambda 3 chain; and the first amino acid has been changed to "Q" in the VH3 chain.

[0059] The skilled worker can use the data in Tables 2a and 2b to design peptide variants that are within the scope

of the present disclosure. It is preferred that variants are constructed by changing amino acids within one or more CDR regions; a variant might also have one or more altered framework regions. With reference to a comparison of the novel antibodies to each other, candidate residues that can be changed include e.g. residues 27 or 51 of the variable light and e.g. residues 32 or 56 of the variable heavy chains of MOR04251, since these are positions of variance vis-à-vis each other. Alterations also may be made in the framework regions. For example, a peptide FR domain might be altered where there is a deviation in a residue compared to a germline sequence.

[0060] With reference to a comparison of the novel antibodies to the corresponding consensus or "master gene" sequence, candidate residues that can be changed include e.g. residues 27, 50 or 90 of the variable light chain of MOR04251 compared to VL λ 3 and e.g. residues 33, 52 or 96 of the variable heavy chain of MOR04251 compared to VH3. Alternatively, the skilled worker could make the same analysis by comparing the amino acid sequences disclosed herein to known sequences of the same class of such antibodies, using, for example, the procedure described by Knappik et al. (2000), and U.S. Patent No. 6,300,064 issued to Knappik et al.

[0061] Furthermore, variants may be obtained by using one MOR as starting point for optimization by diversifying one or more amino acid residues in the MOR, preferably amino acid residues in one or more CDRs, and by screening the resulting collection of antibody variants for variants with improved properties. Particularly preferred is diversification of one or more amino acid residues in CDR-3 of VL, CDR-3 of VH, CDR-1 of VL and/or CDR-2 of VH. Diversification can be done by synthesizing a collection of DNA molecules using trinucleotide mutagenesis (TRIM) technology (Virnekäs et al., 1994).

Conservative Amino Acid Variants

[0062] Polypeptide variants may be made that conserve the overall molecular structure of an antibody peptide sequence described herein. Given the properties of the individual amino acids, some rational substitutions will be recognized by the skilled worker. Amino acid substitutions, *i.e.*, "conservative substitutions," may be made, for instance, on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved.

[0063] For example, (a) nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; (b) polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; (c) positively charged (basic) amino acids include arginine, lysine, and histidine; and (d) negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Substitutions typically may be made within groups (a)-(d). In addition, glycine and proline may be substituted for one another based on their ability to disrupt α -helices. Similarly, certain amino acids, such as alanine, cysteine, leucine, methionine, glutamic acid, glutamine, histidine and lysine are more commonly found in α -helices, while valine, isoleucine, phenylalanine, tyrosine, tryptophan and threonine are more commonly found in β -pleated sheets. Glycine, serine, aspartic acid, asparagine, and proline are commonly found in turns. Some preferred substitutions may be made among the following groups: (i) S and T; (ii) P and G; and (iii) A, V, L and I. Given the known genetic code, and recombinant and synthetic DNA techniques, the skilled scientist readily can construct DNAs encoding the conservative amino acid variants.

[0064] As used herein, "sequence identity" between two polypeptide sequences, indicates the percentage of amino acids that are identical between the sequences. "Sequence homology", indicates the percentage of amino acids that either are identical or that represent conservative amino acid substitutions. Preferred polypeptide sequences of the disclosure have a sequence identity in the CDR regions of at least 60%, more preferably, at least 70% or 80%, still more preferably at least 90% and most preferably at least 95%. Preferred antibodies also have a sequence homology in the CDR regions of at least 80%, more preferably 90% and most preferably 95%.

DNA molecules of the invention

[0065] The present disclosure also relates to the DNA molecules that encode an antibody of the disclosure. These sequences include, but are not limited to, those DNA molecules set forth in Figures 1 a and 2a.

[0066] DNA molecules of the disclosure are not limited to the sequences disclosed herein, but also include variants thereof. DNA variants may be described by reference to their physical properties in hybridization. The skilled worker will recognize that DNA can be used to identify its complement and, since DNA is double stranded, its equivalent or homolog, using nucleic acid hybridization techniques. It also will be recognized that hybridization can occur with less than 100% complementarity. However, given appropriate choice of conditions, hybridization techniques can be used to differentiate among DNA sequences based on their structural relatedness to a particular probe. For guidance regarding such conditions see, Sambrook et al., 1989 (Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) *Molecular Cloning: A laboratory manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA) and Ausubel et al., 1995 (Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Sedman, J. G., Smith, J. A., & Struhl, K. eds. (1995). *Current Protocols in Molecular Biology*. New York: John Wiley and Sons).

EP 1 888 643 B1

[0067] Structural similarity between two polynucleotide sequences can be expressed as a function of "stringency" of the conditions under which the two sequences will hybridize with one another. As used herein, the term "stringency" refers to the extent that the conditions disfavor hybridization. Stringent conditions strongly disfavor hybridization, and only the most structurally related molecules will hybridize to one another under such conditions. Conversely, non-stringent conditions favor hybridization of molecules displaying a lesser degree of structural relatedness. Hybridization stringency, therefore, directly correlates with the structural relationships of two nucleic acid sequences. The following relationships are useful in correlating hybridization and relatedness (where T_m is the melting temperature of a nucleic acid duplex):

a. $T_m = 69.3 + 0.41(G+C)\%$

b. The T_m of a duplex DNA decreases by 1°C with every increase of 1% in the number of mismatched base pairs.

c. $(T_m)_{\mu 2} - (T_m)_{\mu 1} = 18.5 \log_{10} \mu 2 / \mu 1$

where $\mu 1$ and $\mu 2$ are the ionic strengths of two solutions.

[0068] Hybridization stringency is a function of many factors, including overall DNA concentration, ionic strength, temperature, probe size and the presence of agents which disrupt hydrogen bonding. Factors promoting hybridization include high DNA concentrations, high ionic strengths, low temperatures, longer probe size and the absence of agents that disrupt hydrogen bonding. Hybridization typically is performed in two phases: the "binding" phase and the "washing" phase.

[0069] First, in the binding phase, the probe is bound to the target under conditions favoring hybridization. Stringency is usually controlled at this stage by altering the temperature. For high stringency, the temperature is usually between 65°C and 70°C , unless short (< 20 nt) oligonucleotide probes are used. A representative hybridization solution comprises 6X SSC, 0.5% SDS, 5X Denhardt's solution and 100 μg of nonspecific carrier DNA. See Ausubel *et al.*, section 2.9, supplement 27 (1994). Of course, many different, yet functionally equivalent, buffer conditions are known. Where the degree of relatedness is lower, a lower temperature may be chosen. Low stringency binding temperatures are between about 25°C and 40°C . Medium stringency is between at least about 40°C to less than about 65°C . High stringency is at least about 65°C .

[0070] Second, the excess probe is removed by washing. It is at this phase that more stringent conditions usually are applied. Hence, it is this "washing" stage that is most important in determining relatedness via hybridization. Washing solutions typically contain lower salt concentrations. One exemplary medium stringency solution contains 2X SSC and 0.1% SDS. A high stringency wash solution contains the equivalent (in ionic strength) of less than about 0.2X SSC, with a preferred stringent solution containing about 0.1 X SSC. The temperatures associated with various stringencies are the same as discussed above for "binding." The washing solution also typically is replaced a number of times during washing. For example, typical high stringency washing conditions comprise washing twice for 30 minutes at 55°C and three times for 15 minutes at 60°C .

[0071] Accordingly, the present disclosure includes nucleic acid molecules that hybridize to the molecules of set forth in Figures 1a and 2a under high stringency binding and washing conditions, where such nucleic molecules encode an antibody or functional fragment thereof having properties as described herein. Preferred molecules (from an mRNA perspective) are those that have at least 75% or 80% (preferably at least 85%, more preferably at least 90% and most preferably at least 95%) homology or sequence identity with one of the DNA molecules described herein.

Functionally Equivalent Variants

[0072] It is recognized that variants of DNA molecules provided herein can be constructed in several different ways. For example, they may be constructed as completely synthetic DNAs. Methods of efficiently synthesizing oligonucleotides in the range of 20 to about 150 nucleotides are widely available. See Ausubel *et al.*, section 2.11, Supplement 21 (1993). Overlapping oligonucleotides may be synthesized and assembled in a fashion first reported by Khorana *et al.*, J. Mol. Biol. 72:209-217 (1971); see also Ausubel *et al.*, *supra*, Section 8.2. Synthetic DNAs preferably are designed with convenient restriction sites engineered at the 5' and 3' ends of the gene to facilitate cloning into an appropriate vector.

[0073] As indicated, a method of generating variants is to start with one of the DNAs disclosed herein and then to conduct site-directed mutagenesis. See Ausubel *et al.*, *supra*, chapter 8, Supplement 37 (1997). In a typical method, a target DNA is cloned into a single-stranded DNA bacteriophage vehicle. Single-stranded DNA is isolated and hybridized with an oligonucleotide containing the desired nucleotide alteration(s). The complementary strand is synthesized and the double stranded phage is introduced into a host. Some of the resulting progeny will contain the desired mutant, which can be confirmed using DNA sequencing. In addition, various methods are available that increase the probability that the progeny phage will be the desired mutant. These methods are well known to those in the field and kits are commercially available for generating such mutants.

Recombinant DNA constructs and expression

5 [0074] The present disclosure further provides recombinant DNA constructs comprising one or more of the nucleotide sequences of the present invention. The recombinant constructs are used in connection with a vector, such as a plasmid, phagemid, phage or viral vector, into which a DNA molecule encoding an antibody of the disclosure is inserted.

[0075] The encoded gene may be produced by techniques described in Sambrook *et al.*, 1989, and Ausubel *et al.*, 1989. Alternatively, the DNA sequences may be chemically synthesized using, for example, synthesizers. See, for example, the techniques described in OLIGONUCLEOTIDE SYNTHESIS (1984, Gait, ed., IRL Press, Oxford).

10 [0076] Recombinant constructs of the disclosure are comprised with expression vectors that are capable of expressing the RNA and/or protein products of the encoded DNA(s). The vector may further comprise regulatory sequences, including a promoter operably linked to the open reading frame (ORF). The vector may further comprise a selectable marker sequence. Specific initiation and bacterial secretory signals also may be required for efficient translation of inserted target gene coding sequences.

15 [0077] The present disclosure further provides host cells containing at least one of the DNAs of the present disclosure. The host cell can be virtually any cell for which expression vectors are available. It may be, for example, a higher eukaryotic host cell, such as a mammalian cell, a lower eukaryotic host cell, such as a yeast cell or a prokaryotic cell, such as a bacterial cell. Introduction of the recombinant construct into the host cell can be effected by calcium phosphate transfection, DEAE, dextran mediated transfection, electroporation or phage infection.

20 Bacterial Expression

[0078] Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and, if desirable, to provide amplification within the host. Suitable prokaryotic hosts for transformation include *E. coli*, *Bacillus subtilis*, *Salmonella typhimurium* and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*.

30 [0079] Bacterial vectors may be, for example, bacteriophage-, plasmid- or phagemid-based. These vectors can contain a selectable marker and bacterial origin of replication derived from commercially available plasmids typically containing elements of the well known cloning vector pBR322 (ATCC 37017). Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is de-repressed/induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period. Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

35 [0080] In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the protein being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of antibodies or to screen peptide libraries, for example, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable.

40 Therapeutic Methods

[0081] Therapeutic methods involve administering to a subject in need of treatment a therapeutically effective amount of an antibody contemplated by the disclosure. A "therapeutically effective" amount hereby is defined as the amount of an antibody that is of sufficient quantity to effectively block the interaction between GM-CSF and its receptor in a treated area of a subject—either as a single dose or according to a multiple dose regimen, alone or in combination with other agents, which leads to the alleviation of an adverse condition, yet which amount is toxicologically tolerable. The subject may be a human or non-human animal (e.g., rat or rhesus).

50 [0082] An antibody of the disclosure might be co-administered with known medicaments, and in some instances the antibody might itself be modified. For example, an antibody could be conjugated to an immunotoxin or radioisotope to potentially further increase efficacy.

[0083] The disclosed antibodies can be used as a therapeutic or a diagnostic tool in a variety of situations where GM-CSF is undesirably expressed or found. Disorders and conditions particularly suitable for treatment with an antibody hereind disclosed are inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis, Crohn's disease, psoriasis, asthma, atopic dermatitis or shock.

55 [0084] To treat any of the foregoing disorders, pharmaceutical compositions for use in accordance with the present disclosure may be formulated in a conventional manner using one or more physiologically acceptable carriers or excipients. An antibody herein disclosed can be administered by any suitable means, which can vary, depending on the type of disorder being treated. Possible administration routes include parenteral (e.g., intramuscular, intravenous, intraarterial,

intraperitoneal, or subcutaneous), intrapulmonary and intranasal, and, if desired for local immunosuppressive treatment, intralesional administration. In addition, an antibody herein disclosed might be administered by pulse infusion, with, e.g., declining doses of the antibody. Preferably, the dosing is given by injections, most preferably intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic. The amount to be administered will depend on a variety of factors such as the clinical symptoms, weight of the individual, whether other drugs are administered. The skilled artisan will recognize that the route of administration will vary depending on the disorder or condition to be treated.

[0085] Determining a therapeutically effective amount of the novel polypeptide, according to this disclosure, largely will depend on particular patient characteristics, route of administration, and the nature of the disorder being treated. General guidance can be found, for example, in the publications of the International Conference on Harmonisation and in REMINGTON'S PHARMACEUTICAL SCIENCES, chapters 27 and 28, pp. 484-528 (18th ed., Alfonso R. Gennaro, Ed., Easton, Pa.: Mack Pub. Co., 1990). More specifically, determining a therapeutically effective amount will depend on such factors as toxicity and efficacy of the medicament. Toxicity may be determined using methods well known in the art and found in the foregoing references. Efficacy may be determined utilizing the same guidance in conjunction with the methods described below in the Examples.

Diagnostic Methods

[0086] GM-CSF is expressed by various cell types including lymphocytes, monocytes, endothelial cells, fibroblasts and some malignant cells; thus, an anti-GM-CSF antibody herein disclosed may be employed in order to image or visualize a site of possible accumulation of GM-CSF in different tissues in a patient. In this regard, an antibody can be detectably labeled, through the use of radioisotopes, affinity labels (such as biotin, avidin, etc.) fluorescent labels, paramagnetic atoms, etc. Procedures for accomplishing such labeling are well known to the art. Clinical application of antibodies in diagnostic imaging are reviewed by Grossman, H. B., Urol. Clin. North Amer. 13:465-474 (1986)), Unger, E. C. et al., Invest. Radiol. 20:693-700 (1985)), and Khaw, B. A. et al., Science 209:295-297 (1980)).

[0087] The detection of foci of such detectably labeled antibodies might be indicative of a site of inflammation, for example. In one embodiment, this examination is done by removing samples of tissue or blood and incubating such samples in the presence of the detectably labeled antibodies. In a preferred embodiment, this technique is done in a non-invasive manner through the use of magnetic imaging, fluorography, etc. Such a diagnostic test may be employed in monitoring the success of treatment of diseases, where presence or absence of GM-CSF is a relevant indicator. The disclosure also contemplates the use of an anti- GM-CSF antibody, as described herein for diagnostics in an ex vivo setting.

Therapeutic And Diagnostic Compositions

[0088] The antibodies herein disclosed can be formulated according to known methods to prepare pharmaceutically useful compositions, wherein an antibody (including any functional fragment thereof) is combined in a mixture with a pharmaceutically acceptable carrier vehicle. Suitable vehicles and their formulation are described, for example, in REMINGTON'S PHARMACEUTICAL SCIENCES (18th ed., Alfonso R. Gennaro, Ed., Easton, Pa.: Mack Pub. Co., 1990). In order to form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain an effective amount of one or more of the antibodies herein disclosed, together with a suitable amount of carrier vehicle.

[0089] Preparations may be suitably formulated to give controlled-release of the active compound. Controlled-release preparations may be achieved through the use of polymers to complex or absorb anti- GM-CSF antibody. The controlled delivery may be exercised by selecting appropriate macromolecules (for example polyesters, polyamino acids, polyvinyl, pyrrolidone, ethylenevinyl-acetate, methylcellulose, carboxymethylcellulose, or protamine, sulfate) and the concentration of macromolecules as well as the methods of incorporation in order to control release. Another possible method to control the duration of action by controlled release preparations is to incorporate anti-GM-CSF antibody into particles of a polymeric material such as polyesters, polyamino acids, hydrogels, poly(lactic acid) or ethylene vinylacetate copolymers. Alternatively, instead of incorporating these agents into polymeric particles, it is possible to entrap these materials in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatine-microcapsules and poly(methylmethacrylate) microcapsules, respectively, or in colloidal drug delivery systems, for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences (1980).

[0090] The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules, or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

EP 1 888 643 B1

Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

[0091] The compositions may, if desired, be presented in a pack or dispenser device, which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

[0092] The disclosure further is understood by reference to the following working examples, which are intended to illustrate and, hence, not limit the disclosure.

EXAMPLES**Example 1: Generation of human GM-CSF specific antibodies from the HuCAL GOLD® Library****A. Phagemid rescue, phage amplification and purification**

[0093] HuCAL GOLD® library was amplified in 2xYT medium containing 34 µg/ml chloramphenicol and 1 % glucose (2xYT-CG). After helper phage infection (VCSM13) at an OD₆₀₀ of 0.5 (30 min at 37°C without shaking; 30 min at 37°C shaking at 250 rpm), cells were spun down (4120 g; 5 min; 4°C), resuspended in 2xYT / 34 µg/ml chloramphenicol / 50 µg/ml kanamycin / 0.25mM IPTG and grown overnight at 22°C. Phages were PEG-precipitated from the supernatant, resuspended in PBS / 20 % glycerol and stored at -80°C. Phage amplification between two panning rounds was conducted as follows: mid-log phase *E. coli* TG1 cells were infected with eluted phages and plated onto LB-agar supplemented with 1 % of glucose and 34 µg/ml of chloramphenicol. After overnight incubation at 30°C, colonies were scraped off and used to inoculate 2xYT-CG until an OD_{600nm} of 0.5 was reached and helper phage added as described above.

B. Pannings with HuCALGOLD®

[0094] For the selection of antibodies recognizing human GM-CSF several panning strategies were applied. In summary, HuCAL GOLD® antibody-phages were divided into three pools comprising different VH master genes. These pools were individually subjected to either a) a solid phase panning on biotinylated human GM-CSF protein (custom made by R&D Systems, Minneapolis, MN) directly coated on neutravidin coated 96well plates (Pierce, Rockford, IL) as solid support for three rounds or b) a solution panning on biotinylated human GM-CSF protein captured onto streptavidin coated Dynabeads (Dyna, Oslo, Norway) for three rounds.

[0095] In detail, for panning on immobilized biotinylated GM-CSF, wells of the neutravidin plate were washed three times with 300 µl PBS. The antigen was diluted to a concentration of 3 µg/ml (200 nM) in PBS and 0.1 ml was coated per well for 2h at room temperature. After two washing steps with 300 µl PBS the wells were incubated with blocking buffer containing 2x Chemiblocker (Chemicon, Temecula, CA) diluted 1:1 in PBS.

[0096] Prior to the selections, 100 µl of HuCAL GOLD® phages were pre-adsorbed in 100µl blocking buffer containing 0.4µl 25% Tween20 for 0.5 h at RT. Blocked phages were transferred in 100µl aliquots to wells of a neutravidin plate for 0.5 h at RT. This step was repeated twice for pre-absorption.

[0097] After washing (2x 300µl PBS) of the coated and blocked neutravidin microtiter plate, 0.1 ml of the pre-adsorbed phages were added to the coated wells and incubated for 1.5 h at RT shaking gently. This incubation was followed by 10 wash cycles with PBS / 0.05% Tween20 at RT.

[0098] Bound phages were eluted by adding 120µl of 20 mM DTT in 10 mM Tris pH 8.0 per well for 10 min at RT. The eluate was removed and added to 14 ml *E. coli* TG1 grown to an OD_{600nm} of 0.6-0.8. Wells were additionally washed with 200µl PBS and this solution was also added to the TG1 cells. Phage infection of *E. coli* was allowed for 45 min at 37°C without shaking. Additionally, 200 µl of TG1 cells grown to an OD_{600nm} of 0.6-0.8 were added to the selection wells for 45 minutes at 37°C without shaking. These TG-1 cells were added to the 14ml culture already containing the phages from the first elution step. After centrifugation for 10 min at 5000rpm, the bacterial pellets were each resuspended in 500µl 2xYT medium, plated on 2xYT-CG agar plates and incubated overnight at 30°C. Colonies were then scraped from the plates and phages were rescued and amplified as described above.

[0099] The second and third rounds of selection were performed in an identical way to the first round of selection with the only difference that the washing conditions after binding of phage were more stringent. Additionally, in the third round of selection, phages were submitted to an additional preadsorption step on streptavidin-coated beads (Dynabeads M-280; Dynal). Eppendorf tubes were blocked with Chemiblocker solution by incubation for 30 min at RT. Of each phage pool 0.3ml were mixed 1:1 with 2xChemiblocker solution containing 0.05% Tween20 and incubated for 1h at RT in the blocked Eppendorf tubes on a rotator. Blocked phages were then transferred to newly blocked Eppendorf tubes and 50µl of Dynabeads M-280 were added for another 30min for preadsorption. Beads were removed using a magnetic device (Dyna MPC-E). Aliquots of 150µl of phages were then transferred to neutravidin plates for further preadsorption as in round 1 and 2 (see above).

EP 1 888 643 B1

[0100] For the solution panning using biotinylated GM-CSF coupled to Dynabeads the following protocol was applied: 1.5 ml Eppendorf tubes were blocked with 1.5 ml 2xChemiblocker diluted 1:1 with PBS over night at 4°C. 200 µl streptavidin coated magnetic beads (Dynabeads M-280; Dynal) were washed 1x with 200 µl PBS and resuspended in 200 µl 1xChemiblocker (diluted in 1x PBS). Blocking of beads was performed in preblocked tubes over night at 4°C. Phages diluted in 500 µl PBS for each panning condition were mixed with 500 µl 2xChemiblocker / 0.1% Tween 1 h at RT (rotator). Preadsorption of phages was performed twice: 50 µl of blocked Streptavidin magnetic beads were added to the blocked phages and incubated for 30 min at RT on a rotator. After separation of beads via a magnetic device (Dyna MPC-E) the phage supernatant (~1ml) was transferred to a new blocked tube and preadsorption was repeated on 50 µl blocked beads for 30 min. Then, 200 nM biotinylated hGM-CSF was added to blocked phages in a new blocked 1.5 ml tube and incubated for 1 h at RT on a rotator. 100 µl of blocked streptavidin magnetic beads were added to each panning phage pool and incubated 10 min at RT on a rotator. Phage bound to biotinylated GM-CSF and therefore immobilized to the magnetic beads were collected with a magnetic particle separator (Dyna MPC-E). Beads were then washed 7x in PBS/0.05% Tween using a rotator, followed by washing another three times with PBS. Elution of phage from the Dynabeads was performed adding 300 µl 20mM DTT in 10mM Tris/HCl pH8 to each tube for 10 min. Dynabeads were removed by the magnetic particle separator and the supernatant was added to 14ml of a *E. coli* TG-1 culture grown to OD_{600nm} of 0.6-0.8. Beads were then washed once with 200 µl PBS and PBS containing additional removed phage was added to the 14 ml *E. coli* TG-1 culture.

[0101] After centrifugation for 10 min at 5000rpm, the bacterial pellets were each resuspended in 500 µl 2xYT medium, plated on 2xYT-CG agar plates and incubated overnight at 30°C. Colonies were then scraped from the plates and phages were rescued and amplified as described above.

[0102] The second and third rounds of the solution panning on biotinylated GM-CSF was performed according to the protocol of the first round except for increasing the stringency of the washing procedure.

C. Subcloning of selected Fab fragments and expression of soluble Fab fragments

[0103] The Fab encoding inserts of the selected HuCAL GOLD[®] phagemids were subcloned into the expression vector pMORPH[®]X9_Fab_FH (Fig 5) to facilitate rapid expression of soluble Fab. The DNA of the selected clones was digested with *Xba*I and *Eco*R I, thereby cutting out the Fab encoding insert (*ompA*-VLCL and *phoA*-Fd), and cloned into the *Xba*I / *Eco*R I digested-vector pMORPH[®]X9_Fab_FH. Fabs expressed in these vectors carry two C-terminal tags (FLAG[™] and 6xHis, respectively) for detection and purification.

D. Microexpression of HuCALGOLD[®]Fab antibodies in *E. coli*

[0104] Single colonies obtained after subcloning into pMORPH[®]X9_Fab_FH were used to inoculate wells of a sterile 96-well microtiter plate containing 100 µl 2xTY/Cm/1% Glu medium per well and grown overnight at 37°C. 5 µl of each TG-1 *E. coli* culture was transferred to a new sterile 96-well microtiter plate containing 100 µl 2xTY/Cm/0.1% Glu medium per well. Microtiter plates were incubated at 30°C shaking at 400 rpm on a microplate shaker until the cultures were slightly turbid (~2-4 hrs) with an OD_{600nm} of 0.5.

[0105] To these expression plates, 20 µl 2xTY/Cm/ 3mM IPTG were added per well (end concentration 0.5 mM IPTG), sealed with a gas-permeable tape and incubated overnight at 30°C shaking at 400 rpm.

Generation of whole cell lysates (BEL extracts)

[0106] To each well of the expression plates, 40 µl BEL buffer (2xBBS/EDTA: 24.7 g/l boric acid, 18.7 g NaCl/l, 1.49 g EDTA/l, pH8) was added containing 2.5 mg/ml lysozyme and incubated for 1 h at 22°C on a microtiter plate shaker (400 rpm). BEL extracts were used for binding analysis by ELISA or a BioVeris M-series[®] 384 analyzer (see Example 2).

E. Expression of HuCAL[®] GOLD Fab antibodies in *E. coli* and purification

[0107] Expression of Fab fragments encoded by pMORPH[®]X9_Fab_FH in TG-1 cells was carried out in shaker flask cultures with 1 l of 2xYT medium supplemented with 34 µg/ml chloramphenicol. After induction with 0.5 mM IPTG, cells were grown at 22°C for 16 h. Whole cell extracts of cell pellets were prepared by French Press and Fab fragments isolated by nickel/NTA chromatography (Qiagen, Hilden, Germany). Concentrations were determined by UV-spectrophotometry (Krebs et al., 2001).

Example 2: Identification of hGM-CSF specific antibodies

[0108] BEL extracts of individual *E. coli* clones selected by the above mentioned panning strategies were analyzed

by ELISA or BioVeris (BioVeris M-series® 384 analyzer) in order to identify clones encoding hGM-CSF specific Fabs.

A. Enzyme Linked Immunosorbent Assay (ELISA) Techniques

5 [0109] Human recombinant biotinylated GM-CSF (R&D Systems) was coated at 1.5 µg/ml in PBS onto Neutravidin microtiter plates for 2h at RT.

[0110] After coating of antigen the wells were blocked with PBS / 0.05 % Tween (PBS-T) with 1% BSA for 1 h at RT. After washing of the wells with PBS-T BEL-extract, purified HuCAL® Fab or control IgGs were diluted in PBS, added to the wells and incubated for 1 h at RT. For detection of the primary antibodies, the following secondary antibodies were
10 applied: alkaline phosphatase (AP)-conjugated AffiniPure F(ab')₂ fragment, goat anti-human, -anti-mouse or -anti-rat IgG (Jackson Immuno Research). For the detection of AP-conjugates fluorogenic substrates like AttoPhos (Roche) were used according to the instructions by the manufacturer. Between all incubation steps, the wells of the microtiter plate were washed with PBS-T three times and three times after the final incubation with secondary antibody. Fluorescence was measured in a TECAN Spectrafluor plate reader.

15

B. Electrochemiluminescence (BioVeris) based binding analysis for detection of GM-CSF binding Fab in lysates

[0111] Alternative to the ELISA experiments for the detection of GM-CSF binding Fab antibodies in *E. coli* lysates (BEL extracts), binding was analyzed in BioVeris M-SERIES® 384 Analyzer BioVeris, Europe, Witney, Oxfordshire, UK).

20 [0112] To this end BEL extract was diluted at least 1:50 and maximally 1:1000 in assay buffer (PBS/0,05%Tween20/0.5%BSA) for use in BioVeris screening. Biotinylated GM-CSF (R&D Systems) was coupled to streptavidin coated paramagnetic beads, Dynabeads (Dyna), at a concentration of 0.1µg/ml. Per well of a 96 or 384 well plate 25 or 15 µl of a 1:25 dilution of the Dynabead-stock solution was used. Beads were washed three times with assay buffer before adding biotinylated GM-CSF for 30 min at RT on a shaker. Beads were then washed three times
25 with assay buffer and finally resuspended in fresh assay buffer. Anti-human (Fab')₂ (Dianova) was ruthenium labelled using the BV-tag™ (BioVeris Europe, Witney, Oxfordshire, UK). This secondary antibody was added to the GM-CSF coupled beads at a concentration of 6µg/ml immediately before use. 100µl or 60µl of diluted BEL extract (see above) of *E. coli* expression cultures containing Fab antibodies was filled into wells of a 96 or 384 well plate and, respectively,
30 25 or 15µl of the GM-CSF coupled beads plus anti-Fab-BV-tag™ secondary antibody mix was added to each well and incubated for 2h at RT on a plate shaking device. The plates were analyzed in a BioVeris M-SERIES® 384 Analyzer.

[0113] After sequence analysis seventy-four (74) unique clones were identified that showed sufficiently strong binding (signal:noise ratio greater than 10:1 in ELISA or 50:1 in BioVeris). These clones were expressed, purified and were tested in functional assays.

35

C. Determination of the molecular specificity and species crossreactivity of selected anti-hGM-CSF Fabs.

[0114] Crossreactivity of the anti-hGM-CSF antibodies was determined to the following analytes: rat and mouse GM-CSF, human IL-3, human IL-4, , human IL-5, , human IL-13, , human M-CSF (all from Peprotech, London, UK). This was performed in a capture set-up by surface plasmon resonance (Biacore 3000, Uppsala, Sweden).

40 [0115] CM5 chips (Biacore, Sweden) were coated with 5000-6000RU anti-F(ab)₂ (Dianova, Affinipure F(ab)₂ Fragment Goat Anti-Human IgG, F(ab)₂ Fragment specific); 80µg/ml 10mM acetate buffer, pH4 on all 4 flow cells, using standard EDC-NHS amine coupling chemistry. On the flow cells 2-4 specific GM-CSF Fabs (20µl of 500nM Fab at a flowrate of 5 µl/ml, 300-400RU) were captured. After capturing of the specific Fab, buffer was injected, to determine the dissociation of anti-Fab/Fab interaction. In a following cycle, the analyte growth factor was injected (20µl, flow rate 20µl/min) at a
45 concentration range between 15 and 2000nM for the determination of the specific signal. Afterwards the achieved buffer sensogram was manually subtracted from the specific one. After each cycle, the flow cells were regenerated with 100mM HCl (5µl).

[0116] Seven HuCAL® anti-hGM-CSF antibodies including MOR03684 and MOR03682 were tested and were specific for human GM-CSF and did not bind to any of the other cytokines or mouse or rat GM-CSF . In contrast Fab MOR03929 showed significant cross reactivity to rat GM-CSF.

50

Example 3: Identification of anti-human GM-CSF Fab candidates that inhibit the interaction between GM-CSF and the GM-CSF receptor alpha

55 [0117] 74 different hGM-CSF specific antibodies which were selected from the HuCAL GOLD® library were tested for the potency to inhibit the interaction between hGM-CSF and its receptor. The interaction was tested in two ways, (i) one being a proliferation assay using the GM-CSF dependent TF-1 cell line (Kitamura et al., 1989) and (ii) the other being a FACS analysis with a recombinant CHO cell line expressing the alpha chain of the GM-CSF receptor. In the TF-1

proliferation assay, the ability of the anti-GM-CSF antibodies to block the interaction of GM-CSF with the endogenous GM-CSF receptor consisting of the alpha and beta chain was analyzed leading to reduction in cell proliferation. In the FACS assay the specific inhibition of the interaction between GM-CSF and the alpha chain of the GM-CSF receptor was determined.

5

A. Cloning and expression of *macaca mulatta* and human GM-CSF

[0118] *Macaca mulatta* GM-CSF full-length cDNA (GenBank accession no.: AY007376) was synthesized by gene synthesis (geneART GmbH, Regensburg, Germany) and cloned into the pCR-Script-Amp vector (Stratagene, LaJolla, CA, USA). Subsequently the cDNA was cloned into the eukaryotic expression vector pcDNA3.1 (+) (Invitrogen, Paisley, UK) yielding pcDNA-macGM-CSF. The cDNA of human GM-CSF (Genbank accession number NP_000749) was cloned by RT-PCR technique from RNA isolated from 1×10^7 TF-1 cells using the RNeasy kit from Qiagen (Hilden, Germany). Reverse transcription was performed with the SuperscriptII kit using random hexamers (Gibco) followed amplification of the GM-CSF cDNA by PCR. The obtained PCR-product was cloned into expression vector pcDNA3.1(+) yielding pcDNA-huGM-CSF.

10

[0119] HEK293 cells were transiently transfected with these expression vectors respectively using lipofectamine (Stratagene, LaJolla, USA). The medium containing the secreted recombinant macaca or human GM-CSF was harvested 4 days after transfection.

15

B. Inhibition of GM-CSF dependent proliferation of TF-1 cells by anti-hGM-CSF Fabs using human or macaca GM-CSF

[0120] TF-1 (Kitamura et al., 1989) cells were grown according to the provider's protocol (DSMZ, Braunschweig, Germany; DSMZ No. ACC 334). TF-1 cells were washed twice with RPMI1640 medium (10% FCS) and then seeded at a concentration of 2×10^5 cells/ml in $50 \mu\text{l}$ per well of a flat bottom 96well cell culture dish. Human recombinant GM-CSF ("Leucomax", ESSEX Pharma, München) at 0.5ng/ml and HuCAL[®] Fab antibodies (200ng/ml - 200 $\mu\text{g/ml}$ diluted in RPMI1640 medium, 10% FCS) were mixed for 30 min and $50 \mu\text{l}$ of the mix was added to the TF-1 cells, so that the final concentration of GM-CSF was 0.25ng/ml. Maximal cell proliferation (0% inhibition) was measured incubating TF-1 cells at a final GM-CSF of concentration of 0.25ng/ml, without the addition of antibody. 100% inhibition of TF-1 proliferation was measured by omitting GM-CSF from the assay and keeping the cells in RPMI1640 medium (10% FCS) only. TF1 cells were then incubated for 72 hours at 37°C with 5% CO₂ in a humidified chamber. Cell vitality was measured by adding MTT or XTT reagent (Roche, Mannheim, Germany) according to the manufacturer's recommendation. Overall 19 Fab were identified that showed significant inhibition of TF-1 proliferation. The binders MOR03682, MOR03684 and MOR03929 showed consistent inhibition of TF1 cell proliferation of greater than 50% at a concentration of $2 \mu\text{M}$. The inhibitory activity of these non-optimized Fabs was not strong enough to determine an IC₅₀ dose, because full inhibition could not be achieved. In comparison, monoclonal antibodies BVD2-21C11 (BD Biosciences Pharmingen; Cat#554503) and MAB215 (R&D Systems; Cat#MAB215) were able to fully inhibit TF-1 proliferation.

25

30

35

[0121] Additionally, binding of MOR03682 and MOR03684 to native human GM-CSF was tested in the TF-1 proliferation assay. Instead of adding purified human recombinant GM-CSF to the TF-1 cells a supernatant of 5637 cells (DSMZ No. ACC 35) that secrete native human GM-CSF into the medium was used. From a dose response curve comparing the effect of recombinant human GM-CSF with different dilutions of the 5637 supernatant it was determined that the medium contained $\sim 5 \text{ ng/ml}$ of native human GM-CSF. By preincubation of the 5637 supernatant with anti-human GM-CSF Fab MOR03682 or MOR03684 the binding of native human GM-CSF to the TF-1 cells was blocked so that the viability of cells was reduced comparably to the experiment with recombinant human GM-CSF. MOR03684 and MOR03682 thus binds to native human GM-CSF. Fab MOR03929 was not tested in this assay.

40

45

[0122] Additionally, the cross reactivity to macaca GM-CSF was tested in the TF-1 proliferation assay. Instead of adding purified human GM-CSF to the TF-1 cells a supernatant of transfected HEK293 cells that secrete recombinant macaca GM-CSF into the medium was used.

[0123] TF-1 cells proliferated in the presence of macaca GM-CSF containing supernatant but not in the presence of supernatant from untransfected HEK293 cells. From a dose response curve comparing the effect of recombinant human GM-CSF with different dilutions of the HEK-293 medium it was determined that the medium of the transfected cells contained $\sim 2 \mu\text{g/ml}$ macaca GM-CSF. By preincubation of the macaca GM-CSF supernatant with anti-human GM-CSF Fab MOR03682 or MOR03684 the binding of macaca GM-CSF to the TF-1 cells was blocked so that the viability of cells was significantly reduced. MOR03682 and MOR03684 thus are cross-reactive with macaca GM-CSF. Fab MOR03929 was not tested in this assay.

50

55

C. Blocking of GM-CSF binding to the GM-CSF receptor alpha by anti-hGM-CSF Fabs

[0124] In order to test binding of GM-CSF to a cell surface expressed GM-CSF receptor alpha chain the cDNA was cloned into an expression vector and stably transfected into CHO-K1 cells (DSMZ ACC 110).

Cloning of a stable CHO-K1 cell line expressing the alpha chain of the GM-CSF receptor

[0125] The cDNA of the human GM-CSF receptor alpha chain (Genbank accession number M64445) was cloned by RT-PCR technique from RNA isolated from 1×10^7 TF-1 cells using the RNeasy kit from Qiagen (Hilden, Germany). Reverse transcription was performed with the SuperscriptII kit using random hexamers (Gibco). The GM-CSF-receptor alpha chain cDNA was then amplified using the following primers:

5': N-GCRa-plusSS: TTCTCTGGATCCGCCACCATGCTTCTCCTGGTGACAAGCC and
3': C-flGCRa: ACCCTCCAATTGTCAGGTAATTCCTTCACGGTC.

[0126] The PCR reaction yielded a product of ~1250bp which was digested with *EcoRI* and *BamHI* (New England BioLabs). The expression vector pcDNA3.1(+) (Invitrogen, Paisley, UK) was digested with the same enzymes. After purification of the digested vector and PCR product, the fragments were ligated and transformed by electroporation into *E.coli* DH10B cells. Correct clones were identified after preparation of plasmid DNA and sequencing. Correct clones (pcDNA3.1(+)-GM-CSFRalpha) contained the full length human GM-CSF receptor alpha cDNA.

[0127] CHO-K1 cells were grown according to the provider's protocol (DSZM, Braunschweig, Germany; DSMZ No. ACC 110). For transfection cells were grown to 80% confluence in a 6-well plate and incubated with 5 µg DNA of pcDNA3.1(+)-GM-CSFRalpha mixed with 10 µl of the Lipofectamine 2000 reagent (Invitrogen). After 48h cells were fed with 1mg/ml G418 (Gibco) and after another 24h medium was replaced with such containing 2mg/ml G418. After two weeks single cells were seeded into wells of a 96-well culture dish. Single clones were grown up and 5×10^5 cells of each clone were tested for GM-CSFR-alpha expression by FACS analysis using murine IgG MAB1006 (Chemicon International, Temecula, CA) as primary antibody at a concentration of 1 µg/ml and (R-PE-AffiniPure (Fab')₂ Goat-anti-mouse-IgG (Dianova) as secondary antibody at a 1:200 dilution. Primary and secondary antibodies were incubated with the cells for 1h sequentially, while cells were washed in FACS buffer (PBS, 3%FCS) between these steps. Fluorescence of stained cells was quantified in the FL2 channel using a FACSCalibur system (Becton Dickinson).

[0128] Among the clones analyzed clone CHO-GMRa#11 showed the highest median fluorescent intensity. A median fluorescence value (MFL value) of 157 was determined for CHO-GMRa#11 (Fig. 6)

FACS analysis of GM-CSF binding to the GM-CSF receptor alpha expressed on CHO-GMRa#11:

[0129] Prior to adding to cells, antibodies at increasing concentrations (0.1 to 100 µg/ml) were co-incubated with biotinylated GM-CSF (0.5 µg/ml) in FACS buffer (PBS/3%FBS/NaN₃0,05%) for 30min at RT.

[0130] All stainings were performed in round bottom 96-well culture plates (Nalge Nunc) with $1-5 \times 10^5$ cells per well. 2×10^5 CHO-GMRa#11 cells were taken up in 50 µl of the antibody/GM-CSF containing FACS buffer and incubated at 4°C for 1h. Cells were then washed once with 150 µl FACS buffer/well and taken up in 100 µl phycoerythrin-labeled streptavidin (BD Biosciences Pharmingen) which has been diluted 1:400 in FACS buffer. After 1h incubation at 4°C cells were washed twice with FACS buffer, resuspended in 100 µl of FACS buffer and binding of biotinylated GM-CSF was measured via FL2 fluorescence intensity of cells in FACSCalibur (Becton Dickinson). IC₅₀ values were determined from the dose response curves obtained using GraphPad Prism v3.03 software applying a non-linear regression curve fit.

[0131] Fab antibodies MOR03682, MOR03684 and MOR03929 showed significant inhibition of GM-CSF binding to the cell surface expressed GM-CSF receptor alpha.

Example 4: Affinity maturation of selected Fab by stepwise exchange of CDR cassettes**A. Generation of affinity maturation Fab libraries and pannings**

[0132] In order to increase the affinity and inhibitory activity of the anti-GM-CSF Fab fragments clones MOR03682, MOR03684 and MOR03929 were subjected to affinity maturation. In this regard, CDR regions were optimized by cassette mutagenesis using trinucleotide directed mutagenesis (Virnekäs *et al.*, 1994; Nagy *et al.*, 2002). Sequence analysis revealed no sequence homology between the CDRs of the three parental clones analyzed. Table 2a and 2b provide the six CDR peptide sequences for the parental clones MOR03682, MOR03684 and MOR03929.

[0133] The following briefly describes the protocol used for Fab optimization. Fab fragments from expression vector pMORPH®X9Fab_FH were cloned into a phagemid vector (US 6,753,136). Then, two different strategies were applied

EP 1 888 643 B1

to optimize the affinity and efficacy of the parental Fabs.

[0134] First, one phage antibody Fab library was generated where the L-CDR3 of each parental was replaced by a repertoire of individual lambda light chain CDR3 sequences. In a second library the H-CDR2 region was replaced by a repertoire of individual heavy chain CDR2 sequences.

5 **[0135]** Affinity maturation libraries were generated by transforming the diversified clones into *E. coli* TOP10F' (Invitrogen). Phages were prepared as described in Example 1A. Both L-CDR3 libraries of MOR03684 and MOR03682 were pooled and both H-CDR2 libraries derived from MOR03684 and MOR03682 were pooled, while the L-CDR3 and H-CDR2 libraries derived from MOR03929 were kept separately during the selection procedure. Pannings were performed on biotinylated GM-CSF in solution for three rounds essentially as described in Example 1B and applying more stringent selection conditions.

B. Electrochemiluminescence (BioVeris) based binding analysis for detection of improved GM-CSF binding Fab in lysates

15 **[0136]** For the detection of GM-CSF binding Fab antibodies in *E. coli* lysates (BEL extracts), binding was analyzed in the BioVeris M-384 SERIES[®] Workstation (BioVeris Europe, Witney, Oxfordshire, UK) essentially as described in Example 2B.

[0137] Fabs with the highest ECL values were purified and subjected to affinity measurement by solution equilibrium titration (SET; Haenel et al, 2005) and surface plasmon resonance (Biacore) (see Example 4D)

C. X-cloning of improved VL (L-CDR3) with improved VH (H-CDR2)

20 **[0138]** For a further improvement of affinity the independently optimized H-CDR2 and L-CDR3 from matured Fabs which were derived from the same parental clone were combined, because there was a high probability that this combination would lead to a further gain of affinity (Yang et al., 1995; Schier et al., 1996; Chen et al., 1999). This procedure, called X-cloning, was applied for binders that were derived from the parental clone MOR03929 as Fabs with improved affinities were identified from both the H-CDR2 and the L-CDR3 library. This was accomplished by transferring whole light chains (XbaI/SphI fragment) from the L-CDR3-optimized donor clone to the H-CDR2-optimized acceptor clone.

30 **Table 3: X-cloning combinations**

Parental	VH donor		VL donor	Affinity Improved Fab after X-cloning
MOR03929	MOR04287	x	MOR04302	MOR04350
	MOR04290			MOR04354
	MOR04252			MOR04357
MOR03682	MOR04283	x	MOR04297	MOR04342

35 **[0139]** For the resulting 4 Fabs the VL and VH was sequenced to confirm transfer of the correct VL to the respective H-CDR2 improved vector backbone. Table 2a and 2b show the VH and VL protein sequences of all derivatives of MOR03929 and 3682, which are listed in table 3.

D. Determination of picomolar affinities using Solution Equilibrium Titration (SET) and surface plasmon resonance (Biacore)

45 **[0140]** For K_D determination, monomer fractions (at least 90% monomer content, analyzed by analytical SEC; Superdex75, Amersham Pharmacia) of Fab were used. Electrochemiluminescence (ECL) based affinity determination in solution and data evaluation were basically performed as described by Haenel et al., 2005: A constant amount of Fab was equilibrated with different concentrations (serial 5ⁿ dilutions) of human GM-CSF (*Leucomax*) in solution. Biotinylated human GM-CSF (R&D Systems) coupled to paramagnetic beads (M-280 Streptavidin, Dynal) and BV-tag[™] (BioVeris Europe, Witney, Oxfordshire, UK) labeled anti-human (Fab)₂' (Dianova) was added and incubated for 15 - 30 min. Subsequently, the concentration of unbound Fab was quantified via ECL detection using a M- SERIES[®] 384 analyzer (BioVeris Europe).

50 **[0141]** In accordance with Friguet et al., 1985, care was taken to avoid significant equilibrium shift to solid phase during detection.

[0142] Using the assay conditions described above affinities for the Fabs were determined, which are shown in table 4.

55 **[0143]** Additionally kinetic SPR analysis was performed on an F1 chip (Biacore, Sweden) which was coated with a density of ~100 RU recombinant human GM-CSF (Peprotech) in 10 mM Na-acetate pH 4.5 using standard EDC-NHS

EP 1 888 643 B1

amine coupling chemistry. A respective amount of HSA was immobilized on the reference flow cell. PBS (136 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 1.76 mM KH₂PO₄ pH 7.4) + 0.005 % Tween 20 was used as running buffer. Fab was applied in concentration series of 6.3 - 200 nM at a flow rate of 20 μ l/min. Association phase was set to 60 s and dissociation phase to 120 s (parental) or up to 600 s (affinity optimized). In order to monitor dissociation phase over a longer period, the following conditions, basically according to Drake et al., (2004) were used: Fab was applied in a single concentration of 200 nM; flow rate was set to 100 μ l/min and dissociation phase to 6000 - 18.000 s. On the basis of the off-rates determined under these assay conditions affinities for the Fabs were estimated, which are shown in table 4.

Table 4: Affinities of anti-hGM-CSF Fabs determined by Biacore and solution equilibrium titration (SET)

	Biacore		SET
MORO	K _D (pM)		K _D (pM)
3684	6420		16000
4251	70		7.4
3929	4260		2000
4302	174		63.5
4287	nd		17.9
4252	55		6
4290	122		11.1
4350	19		1.1
4354	21		2.8
4357	7		0.4
3682	nd		11406
4283	nd		113
4297	nd		49.2
4342	nd		4.9

E. Determination of affinities to rat GM-CSF using Solution Equilibrium Titration (SET)

[0144] Affinity determination to rat GM-CSF was done essentially as described in Example 4D using rat-GM-CSF (Peprotech) as analyte in solution instead of human GM-CSF. Affinities were calculated according to Haenel *et al* (2005). In this assay affinity of Fab MOR04357 to rat GM-CSF was determined to be K_D = 1.0 nM.

Example 5: Characterization of optimized anti-human GM-CSF Fabs that inhibit the interaction between GM-CSF and the GM-CSF receptor alpha chain A. GM-CSF receptor alpha binding assay

[0145] The GM-CSF receptor binding assay was performed as described above (Example 3C) using 0.5 μ g/ml (35nM) of biotinylated GM-CSF. Maximal binding of GM-CSF to CHO-GMRa#11 cells (0% inhibition) was measured by incubating cells at a final GM-CSF concentration of 0.5 μ g/ml of biotinylated GM-CSF, without the addition of antibody. 100% inhibition of GM-CSF binding was measured by omitting GM-CSF from the assay. IC₅₀ values were determined from the dose response curves obtained using GraphPad Prism v3.03 software applying a non-linear regression curve fit.

[0146] Fabs with improved affinities, the parental Fabs and monoclonal reference IgGs were analyzed. Table 5 summarizes the IC₅₀ values obtained in these assays. The % inhibition achieved at an antibody concentration of 5 μ g/ml is also given in table 5.

5
10
15
20
25
30
35
40
45
50
55

Table 5: IC₅₀ values of anti-hGM-CSF Fabs in receptor inhibition assay

MOR0#	4251	4357	4354	4350	4252	4287	4290	4302	3684	3929	Mab215	21C11
IC ₅₀ (nM)	53	26	26	24	26	25	27	24	>400	35	no fit*	9
% inhibition at 5µg/ml antibody	~100%	~75%	~75%	~75%	~75%	~75%	~75%	~75%	~25%	~60%	~50%	~100%
*no sigmoidal dose response curve could be fitted in this case												

EP 1 888 643 B1

[0147] This assay qualitatively showed that the Fabs obtained from affinity maturation and X-cloning prevent GM-CSF from binding to the GM-CSF receptor alpha chain and therefore retained the blocking mechanism of their parental Fabs. The assay needed to be performed with a concentration of 35nM (0.5 pg/ml) biotinylated GM-CSF in order to obtain a significant signal in FACS. Therefore 17.5 nM Fab (or 8.75 nM IgG) is theoretically needed to block 50% of the GM-CSF, thus setting a limit for determination of IC₅₀ values.

B. Inhibition of GM-CSF dependent proliferation of TF-1 by anti-hGM-CSF Fabs using human GM-CSF

[0148] TF-1 proliferation assay was performed as described in Example 3B. Fab with improved affinities and the parental Fabs as well as monoclonal reference IgGs were analyzed. IC₅₀ values were determined from the dose response curves obtained using GraphPad Prism v3.03 software applying a non-linear regression curve fit. Table 6 summarizes the IC₅₀ values obtained in these assays.

Table 6: IC₅₀ values of anti-hGM-CSF Fabs and control IgGs in TF-1 proliferation assay

MOR0#	4251	4357	4354	4350	4252	4287	4290	4302	3684	3929	Mab215	BVD2-21C11
IC ₅₀ (pM)	463	90	56	82	2010	3382	696	10678	>200000	>200000	4315	6560
IC ₅₀ x-fold im- proved compared to Mab215	9.3	47.9	77.1	52.6	2.1	1.3	6.2	-	-	-	-	-
IC ₅₀ x-fold im- proved compared to BVD2-21C11	14.2	72.9	117.1	80.0	3.2	1.9	9.4	-	-	-	1.5	-

[0149] In another set of experiments IC₅₀ values in the TF-1 proliferation assay were determined for the parental Fab MOR03682, its affinity matured derivatives MOR04283, MOR04297 and the x-cloned variant MOR04342. Table 7 summarizes the IC₅₀ values obtained in these assays.

Table 7: IC₅₀ values of anti-hGM-CSF Fabs in TF-1 proliferation assay

MOR0#	4342	4283	4297	3682
IC ₅₀ (pM)	80	17293	13975	>200000

[0150] These experiments demonstrated the large improvements achieved in IC₅₀ values after affinity maturation and X-cloning. For example, MOR04357, MOR04350, MOR04354 show >2000fold improved IC₅₀ values compared to their parental MOR03929 and exceed the potency of BVD2-21C11 and Mab215

Example 6: Conversion of MOR04357 to human IgG1 format**A. Gene optimization of Fab DNA sequences for expression in mammalian expression systems.**

5 [0151] To optimize DNA of the VH and VL of MOR04357 for mammalian gene expression (e.g. changing codon usage, GC content, etc.) GeneOptimizer™ software from Geneart (Regensburg, Germany) was utilized to define such optimized VH and VL DNA sequences, which were gene synthesized at Geneart (Regensburg, Germany) and cloned into pPCR-Script vectors yielding 055906pPCR-Script and 055907pPCR-Script. SEQ ID NO: 48 shows the respective VH sequence, while SEQ ID NO: 57 shows the respective VL sequence.

10

B. Cloning of Fab MOR04357 into human IgG1 format and IgG1 expression

[0152] In order to express full length immunoglobulin (Ig), variable domain fragments of the gene optimized heavy (VH) and light chains (VL) were subcloned from the pPCR-Script vectors (Example5a) into the the pMORPH®2_h_Ig vector series for human IgG1. Codon-optimized VH of MOR04357 was isolated from 055906pPCR-Script via *NheI/BspI* digestion and inserted into pMorph2_h_IgG1f master vector cut with the same restriction enzymes. This vector already contained a human gamma 1 constant region. The resulting expression plasmid was termed pMorph2_h_IgG1f_MOR04357_co. Codon-optimized VL of MOR04357 was isolated from 055907pPCR-Script via *NheI/HpaI* digestion and inserted into pMorph2_h_Iglambda2 master vector cut with the same restriction enzymes. This vector already contained a human lambda constant region. The resulting expression plasmid was termed pM2_h_Iglambda2_MOR04357_co.

20

C. Transient Expression and Purification of Human IgG

25 [0153] Eukaryotic HKB11 cells were transfected with an equimolar amount of IgG heavy and light chain expression vector DNA. Cell culture supernatant was harvested from 3 to 7 days post transfection. After adjusting the pH of the supernatant to 8.0 and sterile filtration, the solution was subjected to standard protein A affinity chromatography (rProteinA FF or MabSelect SURE, GE Healthcare). Buffer exchange was performed to 1 x Dulbecco's PBS (pH 7,2, Invitrogen) and samples were sterile filtered (0,2 µm). MOR04357 IgG1 was dialysed against 1 x Dulbecco's PBS (pH 6,5, Invitrogen). Purity of IgG was analysed under denaturing, reducing conditions in SDS-PAGE or by using Agilent BioAnalyzer and in native state by SE-HPLC.

30

D. Determination of picomolar affinities using Solution Equilibrium Titration (SET)

35 [0154] For K_D determination, monomer fractions (at least 90% monomer content, analyzed by analytical SEC; Superdex75, Amersham Pharmacia) of IgG1 were used. Electrochemiluminescence (ECL) based affinity determination in solution and data evaluation were basically performed as described by Haenel et al., 2005 and as described in Example4B. The K_D values for MOR04357 IgG1 against human recombinant GM-CSF was determined to be 1.1 pM.

40

E. Determination of affinities to rat GM-CSF using Solution Equilibrium Titration (SET)

[0155] Affinity determination to rat GM-CSF was done essentially as described in Example 4D using rat-GM-CSF (Peprotech) as analyte in solution instead of human GM-CSF. Affinities were calculated according to Haenel *et al* (2005). The K_D value for the MOR04357 IgG1 against rat recombinant GM-CSF was determined to be 130 pM.

45

Example 7: Characterization of MOR04357 IgG1 derived from optimized anti-human GM-CSF Fabs**A. Inhibition of GM-CSF dependent proliferation of TF-1 by anti-bGM-CSF IgGs using human and rhesus GM-CSF**

50 [0156] TF-1 proliferation assay was performed as described in Example 3B. MOR04357 was analyzed in IgG1 format and as control monoclonal reference IgGs were analyzed. IC_{50} values were determined from the dose response curves obtained using GraphPad Prism v3.03 software applying a non-linear regression curve fit. Table 8 summarizes the IC_{50} values obtained in these assays. Three different variants of GM-CSF were used in this assay: Firstly, recombinant human GM-CSF at a concentration of 0.25 ng/ml, produced in *E. coli*, secondly, culture supernatant from HEK293 which have been transiently transfected with pcDNA-huGM-CSF (see Example 3A), containing recombinant human GM-CSF and thirdly, culture supernatant from HEK293 cells which have been transiently transfected with pcDNA-macGM-CSF (see Example 3A), containing recombinant *macaca mulatta* (rhesus) GM-CSF. For TF-1 proliferation assays the HEK293 culture supernatants were used as a source of the respective GM-CSF in such dilutions that TF-1 cells showed a similar

55

EP 1 888 643 B1

proliferation as compared to proliferation given at the defined concentration of 0.25 ng/ml purified recombinant human GM-CSF produced in *E.coli*.

Table 8: IC₅₀ values of MOR04357 IgG and control IgGs in TF-1 proliferation assay

	IC ₅₀ (pM)		
	human GM-CSF (<i>E.coli</i>)	human GM-CSF (HEK293)	macaca GM-CSF (HEK293)
MOR04357 IgG1	48	11	15
21C11	1668	144	128
Mab215	625	54	190

[0157] This experiment demonstrated the large improvements achieved in IC₅₀ values after affinity maturation and X-cloning where preserved after conversion from Fab to IgG1 format. IgG1 MOR04357 shows >2000fold improved IC₅₀ values compared to Fab MOR03929 and exceeds the potency of BVD2-21 C11 and Mab215.

References:**[0158]**

Alvaro-Gracia JM, Zvaifler NJ, Brown CB, Kaushansky K, and Firestein GS. (1991). Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha. *J Immunol* 146, 3365-3371.

Babior, B. (2000). Phagocytes and oxidative stress. *Am J Med* 109, 33-44.

Bonfield, T.L., Kavuru, M.S., and Thomassen, M.J. (2002). Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis. *Clin Immunol* 105, 342-350.

Bozinovski, S., Jones, J., Beavitt, S.J., Cook, A.D., Hamilton, J.A., and Anderson, G.P. (2003). Innate immune responses to lipopolysaccharide in mouse lung are suppressed and reversed by neutralization of GM-CSF via repression of TLR-4. *Am J Physiol Lung Cell Mol Physiol*.

Broide, D.H. and Firestein, G.S. (1991). Endobronchial allergen challenge in asthma. Demonstration of cellular source of granulocyte macrophage colony-stimulating factor by in situ hybridization. *J Clin Invest* 88, 1048-1053.

Broide, D.H., Paine, M.M., and Firestein, G.S. (1992). Eosinophils express interleukin 5 and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. *J Clin Invest* 90, 1414-1424.

Brown, C.B., Pihl, C.E., and Kaushansky, K. (1994). Mapping of human granulocyte-macrophage-colony-stimulating-factor domains interacting with the human granulocyte-macrophage-colony-stimulating-factor-receptor alpha-subunit. *Eur J Biochem* 225, 873-880.

Burmester, G.R., Stuhlmüller, B., Keyszer, G., and Kinne, R.W. (1997). Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis? *Arthritis Rheum* 40, 5-18.

Campbell, I.K., Bendele, A., Smith, D.A., and Hamilton, J.A. (1997). Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice. *Ann Rheum Dis* 56, 364-368.

Campbell, I.K., Rich, M.J., Bischof, R.J., Dunn, A.R., Grail, D., and Hamilton, J.A. (1998). Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. *J Immunol* 161, 3639-3644.

Carrieri, P.B., Provitera, V., De Rosa, T., Tartaglia, G., Gorga, F., and Perella, O. (1998). Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity. *Immunopharmacol Immunotoxicol*. 20, 373-382.

Cebon, J., Nicola, N.A., Ward, M., Gardner, I., Dempsey, P.J., Layton, J.E., Dührsen, U., Burgess, A., Nice, E.C., and

Morstyn,G. (1990). Granulocyte-macrophage stimulating factor from human lymphocytes. *J Biol Chem* 265, 4483-4491.

5 Chantry,D., Tumer,M., Brennan,F., Kingsbury,A., and Feldmann,M. (1990). Granulocyte-macrophage colony stimulating factor induces both HLA-DR expression and cytokine production by human monocytes. *Cytokine* 2, 60-67.

10 Chen Y., Wiesmann C., Fuh G., Li B., Christinger H.W., McKay .P, de Vos A.M., Lowman H.B. (1999) Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. *J Mol Biol.* 293, 865-81.

Cheng,S.S., Lai,J.J., Lukacs,N.W., and Kunkel,S.L. (2001). Granulocyte-macrophage colony stimulating factor up-regulates CCR1 in human neutrophils. *J Immunol* 166, 1178-1184.

15 Clark,S.C. and Kamen,R. (1987). The human hematopoietic colony-stimulating factors. *Science* 236, 1229-1237.

Cook,A.D., Braine,E.L., Campbell,I.K., Rich,M.J., and Hamilton,J.A. (2001). Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. *Arthritis Res* 3, 293-298.

20 de Groot,R.P., Coffey,P.J., and Koenderman,L. (1998). Regulation of proliferation,differentiation and survival by the IL-3/IL-5/GM-CSF receptor family. *Cell Signal.* 10, 619-628.

25 de Vries,E.G., Willemse,P.H., Biesma,B., Stem,A.C., Limburg,P.C., and Vellenga,E. (1991). Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. *Lancet* 338, 517-518.

Diederichs,K., Boone,T., and Karplus,P.A. (1991). Novel fold and putative receptor binding site of granulocyte-macrophage colony-stimulating factor. *Science* 254, 1779-1782.

30 Drake A.W., Myszka D.G., Klakamp S.L. (2004) Characterizing high-affinity antigen/antibody complexes by kinetic and equilibrium-based methods. *Anal Biochem.* 328, 35-43.

35 Dranoff,G., Crawford,A.D., Sadelain,M., Ream,B., Rashid,A., Bronson,R.T., Dickersin,G.R., Bachurski,C.J., Mark,E.L., Whitsett,J.A., and (1994). Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. *Science* 264, 713-716.

Friguet B., Chaffotte A.F, Djavadi-Ohanian L., Goldberg M.E. (1985), Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. *J Immunol Methods.* 77, 305-19.

40 Gasson,J.C., Baldwin,G.C., Sakamoto,K.M., and DiPersio,J.F. (1990a). The biology of human granulocyte-macrophage colony-stimulating factor (GM-CSF). *Prog Clin Biol Res* 352, 375-384.

Gasson,J.C., Fraser,J.K., and Nimer,S.D. (1990b). Human granulocyte-macrophage colony-stimulating factor (GM-CSF): regulation of expression. *Prog Clin Biol Res* 338, 27-41.

45 Gasson,J.C., Kaufman,S.E., Weisbart,R.H., Tomonaga,M., and Golde,D.W. (1986). High-affinity binding of granulocyte-macrophage colony-stimulating factor to normal and leukemic human myeloid cells. *Proc Natl Acad Sci USA.* 83, 669-673.

50 Gearing,D.P., King,J.A., Gough,N.M., and Nicola,N.A. (1989). Expression cloning of a receptor for human granulocyte-macrophage colony-stimulating factor. *EMBO J.* 12, 3667-3676.

Gomez-Cambronero,J., Horn,J., Paul,C.C., and Baumann,M.A. (2003). Granulocyte-macrophage colony-stimulating factor is a chemoattractant cytokine for human neutrophils: involvement of the ribosomal p70 S6 kinase signaling pathway. *J Immunol* 171, 6846-6855.

55 Haenel, C., Satzger, M., Della Ducata, D., Ostendorp, R. and Brocks, B. (2005). Characterization of high-affinity antibodies by electrochemiluminescence-based equilibrium titration. *Analytical Biochemistry*, 339, 1, 182-184.

Hamilton, J.A. (1993). Rheumatoid arthritis: opposing actions of hemopoietic growth factors and slow acting anti-rheumatic drugs. *Lancet* 342, 536-539.

Hamilton, J.A. (2002). GM-CSF in inflammation and autoimmunity. *Trends Immunol* 23, 403-408.

5

Hart, P.H., Whitty, G.A., Piccoli, D.S., and Hamilton, J.A. (1988). Synergistic activation of human monocytes by granulocyte-macrophage colony-stimulating factor and IFN-gamma. Increased TNF-alpha but not IL-1 activity. *J Immunol* 141, 1516-1521.

10

Haworth, C., Brennan, F.M., Chantry, D., Turner, M., Maini, R.N., and Feldmann, M. (1991). Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. *Eur J Immunol* 21, 2575-2579.

15

Hayashida, K., Kitamura, T., Gorman, D.M., Arai, K., Yokota, K., and Miyajima, A. (1990). Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): reconstitution of a high-affinity GM-CSF receptor. *Proc Natl Acad Sci U S A* 87, 9655-9659.

20

Hazenber BP, Van Leeuwen MA, Van Rijswijk MH, Stem AC, and Vellenga E (1989). Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis. *Blood* 74, 2769-2780.

Kastelein, R.A. and Shanafelt, A.B. (1993). GM-CSF receptor: interactions and activation. *Oncogene* 8, 231-236.

25

Kaufman, S.E., DiPersio, J.F., and Gasson, J.C. (1989). Effects of human GM-CSF on neutrophil degranulation in vitro. *Exp Hematol* 17, 800-804.

Kitamura, T., Sato, N., Arai, K., and Miyajima, A. (1991). Expression cloning of the human IL-3 receptor cDNA reveals a shared beta subunit for the human IL-3 and GM-CSF receptors. *Cell* 66, 1165-1174.

30

Kitamura, T., Tanaka, N., Watanabe, J., Uchida, Kanegasaki, S., Yamada, Y., and Nakata, K. (1999). Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. *J Exp Med* 190, 875-880.

35

Kitamura T., Tange T., Terasawa T., Chiba S., Kuwaki T., Miyagawa K., Piao Y.F., Miyazono K., Urabe A., Takaku F. (1989). Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin *J Cell Physiol.* 140, 323-34.

40

Knappik, A., Ge, L., Honegger, A., Pack, P., Fischer, M., Wellnhofer, G., Hoess, A., Wolle, J., Pluckthun, A., and Vimekas, B. (2000). Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. *J Mol Biol* 296, 57-86.

45

Krebs, B., Rauchenberger, R., Reiffert, S., Rothe, C., Tesar, M., Thomassen, E., Cao, M., Dreier, T., Fischer, D., Hoss, A., Inge, L., Knappik, A., Marget, M., Pack, P., Meng, X.Q., Schier, R., Sohlmann, P., Winter, J., Wolle, J., and Kretzschmar, T. (2001). High-throughput generation and engineering of recombinant human antibodies. *J Immunol Methods* 254, 67-84.

50

Lopez, A.F., Williamson, D.J., Gamble, J.R., Begley, C.G., Harlan, J.N., Klebanoff, S.J., Waltersdorff, A., Wong, G., Clark, S.C., and Vadas, M.A. (1986). Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. *J Clin Invest* 78, 1220-1228.

55

McQualter, J.L., Darwiche, R., Ewing, C., Onuki, M., Kay, T.W., Hamilton, J.A., Reid, H.H., and Bernard, C.C. (2001). Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. *J Exp Med* 194, 873-882.

Meager, A., Wadhwa, M., Bird, C., Dilger, P., Thorpe, R., Newsom-Davis, J., and Willcox, N. (1999). Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease. *Immunology* 97, 526-532.

EP 1 888 643 B1

Metcalf,D., Begley,C.G., Johnson,G.R., Nicola,N.A., Vadas,M.A., Lopez,A.F., Williamson,D.J., Wong,G.G., Clark,S.C., and Wang,E.A. (1986). Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. *Blood* 67, 37-45.

5 Mulherin,D., Fitzgerald,O., and Bresnihan,B. (1996). Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. *Arthritis Rheum* 39, 115-124.

10 Nagy Z.A., Hubner B., Lohning C., Rauchenberger R., Reiffert S., Thomassen-Wolf E., Zahn S., Leyer S., Schier E.M., Zahradnik A., Brunner C., Lobenwein K., Rattel B., Stanglmaier M., Hallek M., Wing M., Anderson S., Dunn M., Kretzschmar T., Tesar M. (2002) Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. *Nat Med.* 8, 801-7

15 Olver,I.N., Hercus,T., Lopez,A., Vadas,M., Somogyi,A.A., Doyle,I., Foster,D.J., Keefe,D., Taylor,A., Brown,M., To,L.B., Cole,J., Rawling,T., Cambareri,B., Myers,M., Olszewski,N., Bastiras,S., Senn,C., Hey,A., Verma,M., and Wigley,P. (2002). A phase I study of the GM-CSF antagonist E21R. *Cancer Chemother Pharmacol* 50, 171-178.

20 Plenz,G., Eschert,H., Beissert,S., Arps,V., Sindermann,J.R., Robenek,H., and Völker,W. (2003). Alterations in the vascular extracellular matrix of granulocyte-macrophage colony-stimulating factor (GM-CSF)-deficient mice. *FASEB J.* 17, 1451-1457.

Rapoport,A.P., Abboud,C.N., and DiPersio,J.F. (1992). Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF): receptor biology, signal transduction, and neutrophil activation. *Blood Rev* 6,43-57.

25 Rauchenberger,R., Borges,E., Thomassen-Wolf,E., Rom,E., Adar,R., Yaniv,Y., Malka,M., Chumakov,I., Kotzer,S., Resnitzky,D., Knappik,A., Reiffert,S., Prassler,J., Jury,K., Waldherr,D., Bauer,S., Kretzschmar,T., Yayon,A., and Rothe,C. (2003). Human combinatorial Fab Library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3. *J Biol Chem.*

30 Santiago-Schwarz F, Anand P,L.S., and Carsons SE (2001). Dendritic cells (DCs) in rheumatoid arthritis (RA): progenitor cells and soluble factors contained in RA synovial fluid yield a subset of myeloid DCs that preferentially activate Th1 inflammatory-type responses. *J Immunol* 167, 1758-1768.

35 Sato,N., Sakamaki,K., Terada,N., Arai,K., and Miyajima,A. (1993). Signal transduction by the high-affinity GM-CSF receptor: two distinct cytoplasmic regions of the common beta subunit responsible for different signaling. *EMBO J* 12, 4181-4189.

40 Schier R., McCall A., Adams G..P, Marshall K.W., Merritt H., Yim M., Crawford R.S., Weiner L.M., Marks C., Marks J.D. (1996) Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. *J Mol Biol.* 8, 263:551-67.

45 Shanafelt,A.B., Johnson,K.E., and Kastelein,R.A. (1991a). Identification of critical amino acid residues in human and mouse granulocyte-macrophage colony-stimulating factor and their involvement in species specificity. *J Biol Chem* 266, 13804-13810.

Shanafelt,A.B., Miyajima,A., Kitamura,T., and Kastelein,R.A. (1991b). The amino-terminal helix of GM-CSF and IL-5 governs high affinity binding to their receptors. *EMBO J* 10, 4105-4112.

50 Shibata,Y., Berclaz,P.-Y., Chroneos,Z., Yoshida,H., and Trapnell,B.C. (2001). GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU. *Immunity* 15, 557-567.

Sisson,S.D. and Dinarello,C.A. (1988). Production of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor by human mononuclear cells stimulated with granulocyte-macrophage colony-stimulating factor. *Blood* 72, 1368-1374.

55 Stanley,E., Lieschke,G.J., Grail,D., Metcalf,D., Hodgson,G., Gall,J.A., Maher,D.W., Cebon,J., Sinickas,V., and Dunn,A.R. (1994). Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. *Proc Natl Acad Sci U S A* 91, 5592-5596.

EP 1 888 643 B1

Trapnell, B.C. and Whitsett, J.A. (2002). GM-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. *Annu Rev Physiol* 64, 775-802.

5 Uchida, K., Nakata, K., Trapnell, B.C., Terakawa, T., Hamano, E., Mikami, A., Matsushita, I., Seymour, J.F., Oh-Eda, M., Ishige, I., Eishi, Y., Kitamura, T., Yamada, Y., Hanaoka, K., and Keicho, N. (2004). High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. *Blood* 103, 1089-1098.

10 Virnekäs, B., Ge, L., Plückthun, A., Schneider, K.C., Wellenhofer, G. & Moroney, S.E., (1994). *Nucleic Acids Research* 22, 5600-5607.

15 Xu, W.D., Firestein, G.S., Taetle, R., Kaushansky, K., and Zvaifler, N.J. (1989). Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. *J Clin Invest* 83, 876-882.

Yamashita, N., Tashimo, H., Ishida, H., Kaneko, F., Nakano, J., Kato, H., Horiuchi, T., and Ohta, K. (2002). Attenuation of airway hyperresponsiveness in a murine asthma model by neutralization of GM-CSF. *Cell Immunol* 219, 92-97.

20 Yang W.P., Green K., Pinz-Sweeney S., Briones A.T., Burton D.R., Barbas C.F. 3rd. (1995). CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. *J Mol Biol.* 254, 392-403

25 Zhang, Y., McCluskey, K., Fujii, K., and Wahl, L.M. (1998). Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms. *J Immunol* 161, 3071-3076.

PATENTKRAV

1. Isoleret humant eller humaniseret antistof eller funktionelt fragment deraf, som omfatter en antigenbindingsregion, der er specifik for human GM-CSF og omfatter en
- 5 H-CDR1-sekvens GFTFSSYWMN, en H-CDR2-sekvens GIENKRAGGATFYAASVKG, GIESKWAGGATYYAAGVKG eller GIENKYAGGATYYAASVKG, en H-CDR3-sekvens GFGTDF, en L-CDR1-sekvens SGDSIGKKYAY, en L-CDR2-sekvens KKRPS og en L-CDR3-sekvens SAWGDKGM.
- 10 2. Humant eller humaniseret antistof eller funktionelt fragment deraf ifølge krav 1 omfattende en antigenbindingsregion, der er specifik for human GM-CSF, hvor det isolerede humane eller humaniserede antistof eller funktionelle fragment deraf er i stand til (i) at blokere vekselvirkningen af 0,5 µg/ml human GM-CSF med alfa-kæden i human GM-CSF-receptor, der udtrykkes mindst 50% på ca. 2×10^5 CHO-K1-celler
- 15 under følgende betingelser: (a) koncentrationen af den humane GM-CSF-receptor-alfakæde, der udtrykkes på CHO-K1-cellerne, ligner koncentrationen af den humane GM-CSF-receptor-alfakæde, der udtrykkes på ca. 2×10^5 CHO-GMRa#11-celler, og (b) koncentrationen af det isolerede humane eller humaniserede antistof eller funktionelle fragment deraf er ca. 5 µg/ml; og (ii) at neutralisere 0,25 ng/ml human GM-CSF i en
- 20 TF-1-proliferationsanalyse med en mindst fem gange lavere IC_{50} -værdi end referenceantistoffet BVD2-21C11 (BD Biosciences Pharmingen; Cat#554503) og/eller antistoffet MAB215 (R&D Systems; Cat#MAB215).
3. Humant eller humaniseret antistof eller funktionelt fragment deraf ifølge krav 1
- 25 eller 2, som omfatter en variabel tung kæde valgt blandt
- (a)
- QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWV
SGIENKRAGGATFYAASVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYC
ARGFGTDFWGQGTLVTVSS,
- (b)
- QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWV
SGIESKWAGGATYYAAGVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYY
30 CARGFGTDFWGQGTLVTVSS og _____
- (c)

QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWV
 SGIENKYAGGATYYAASVKGRFTISRDNKNTLYLQMNSLRAEDTAVYY
 CARGFGTDFWGQGTLTVSS.

4. Humant eller humaniseret antistof eller funktionelt fragment deraf ifølge et hvilket som helst af kravene 1 eller 2, som omfatter en variabel let kæde valgt blandt

5 (a)

DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKR
 PSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTKL
 TVLGQ,

(b)

DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKR
 PSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTKL
 TVLGQ og

(c)

DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKR
 PSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTKL
 TVLGQ.

10

5. Humant eller humaniseret antistof eller funktionelt fragment deraf ifølge et hvilket som helst af kravene 1 til 4, som omfatter en H-CDR3-sekvens GFGTDF, en H-CDR2-sekvens GIENKYAGGATYYAASVKG, en H-CDR1-sekvens GFTFSSYWMN og en
 15 L-CDR3-sekvens SAWGDKGM, en L-CDR2-sekvens KKRPS og en L-CDR1-sekvens
 SGDSIGKKYAY.

6. Humant eller humaniseret antistof eller funktionelt fragment deraf ifølge krav 5, som omfatter

20 (a) den variable tunge kæde med sekvensen

QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEW
 VSGIENKYAGGATYYAASVKGRFTISRDNKNTLYLQMNSLRAEDTAV
 YYCARGFGTDFWGQGTLTVSS og

25 (b) den variable lette kæde med sekvensen

DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYK
KRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGG
TKLTVLGQ.

- 5 7. Humant eller humaniseret antistof eller funktionelt fragment deraf ifølge et hvilket som helst af kravene 1 til 6, hvori det humane eller humaniserede antistof eller funktionelle fragment deraf er krydsreaktivt med rotte-GM-CSF og/eller rhesus-GM-CSF.
- 10 8. Humant eller humaniseret antistof eller funktionelt fragment deraf ifølge et hvilket som helst af kravene 1 til 7, hvori antistoffet eller det funktionelle fragment deraf er i stand til at neutralisere human GM-CSF i en TF-1-proliferationsanalyse med mindst 10 gange lavere IC_{50} -værdi end referenceantistoffet MAB215 (R&D Systems; Cat#MAB215) og/eller BVD2-21C11 (BD Biosciences Pharmingen; Cat#554503).
- 15 9. Funktionelt antistoffragment ifølge et hvilket som helst af kravene 1 til 7, som er et Fab- eller scFV-antistoffragment.
- 20 10. Humant eller humaniseret antistof ifølge et hvilket som helst af kravene 1 til 7, som er et humant antistof.
11. Humant eller humaniseret antistof ifølge krav 10, som er et IgG.
- 25 12. Nukleinsyresekvens, der koder for en antigenbindingsregion i et humant eller humaniseret antistof eller et funktionelt fragment deraf ifølge et hvilket som helst af kravene 1 til 11.
13. Nukleinsyresekvens ifølge krav 12, som omfatter
(i) en nukleotidsekvens valgt blandt
- 30 (a)

CAGGTGCAATTGGTGGAAAGCGGCGGCCTGGTGCAACCGGGC
 GGCAGCCTGCGTCTGAGCTGCGCGGCCTCCGGATTTACCTTTTCTT
 CTTATTGGATGAATTGGGTGCGCCAAGCCCCTGGGAAGGGTCTCG
 AGTGGGTGAGCGGTATTGAGAATAAGCGTGCTGGTGGTGTACTT
 TTTATGCTGCTTCCGTAAAGGGTTCGTTTTACCATTTCACGTGATAAT
 TCGAAAAACACCCTGTATCTGCAAATGAACAGCCTGCGTGCGGAA
 GATACGGCCGTGATTATTGCGCGCGTGGTTTTGGTACTGATTTTT
 GGGGCCAAGGCACCCTGGTGACGGTTAGCTCA,

(b)

CAGGTGCAATTGGTGGAAAGCGGCGGCCTGGTGCAACCGGGC
 GGCAGCCTGCGTCTGAGCTGCGCGGCCTCCGGATTTACCTTTTCTT
 CTTATTGGATGAATTGGGTGCGCCAAGCCCCTGGGAAGGGTCTCG
 AGTGGGTGAGCGGTATTGAGTCTAAGTGGGCTGGTGGTGTACTT
 ATTATGCTGCTGGTGTAAAGGGTTCGTTTTACCATTTCACGTGATAA
 TTCGAAAAACACCCTGTATCTGCAAATGAACAGCCTGCGTGCGGA
 AGATACGGCCGTGATTATTGCGCGCGTGGTTTTGGTACTGATTTTT
 TGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA,

(c)

CAGGTGCAATTGGTGGAAAGCGGCGGCCTGGTGCAACCGGGC
 GGCAGCCTGCGTCTGAGCTGCGCGGCCTCCGGATTTACCTTTTCTT
 CTTATTGGATGAATTGGGTGCGCCAAGCCCCTGGGAAGGGTCTCG
 AGTGGGTGAGCGGTATTGAGAATAAGTATGCTGGTGGTGTACTT
 ATTATGCTGCTTCTGTAAAGGGTTCGTTTTACCATTTCACGTGATAA
 TTCGAAAAACACCCTGTATCTGCAAATGAACAGCCTGCGTGCGGA
 AGATACGGCCGTGATTATTGCGCGCGTGGTTTTGGTACTGATTTTT
 TGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA og

5

(d)

CAGGTGCAGCTGGTTCGAGTCTGGCGGCGGACTGGTGCAGCCTGGC
 GGCAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTCAGC
 AGCTACTGGATGAACTGGGTGAGGCAGGCCCTGGCAAGGGCCTG
 GAGTGGGTGTCCGGCATCGAGAACAAGTATGCCGGCGGAGCCACC
 TACTACGCCGCCAGCGTGAAGGGCCGGTTACCATCAGCCGGGAC
 AACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGAGGGCC
 GAGGACACCGCCGTGACTACTGTGCCAGGGGCTTCGGCACCGAT
 TTCTGGGGCCAGGGCACCCCTGGTGACAGTCAGCTCA;

eller

(ii) en nukleinsyresekvens, der under højstringente betingelser hybridiserer til den komplementære streng til sekvensen (i)(a), (i)(b), (i)(c) eller (i)(d).

14. Nukleinsyresekvens ifølge krav 12, som omfatter

5 (i) en nukleotidsekvens valgt blandt

(a)

GATATCGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGT
 CAGACCGCGCGTATCTCGTGTAGCGGCGATTCTATTGGTAAGAAG
 TATGCTTATTGGTACCAGCAGAAACCCGGGCAGGCGCCAGTTCTT
 GTGATTTATAAGAAGCGTCCCTCAGGCATCCCGGAACGCTTTAGC
 GGATCCAACAGCGGCAACACCGCGACCCTGACCATTAGCGGCACT
 CAGGCGGAAGACGAAGCGGATTATTATTGCTCTGCTTGGGGTGAT
 AAGGGTATGGTGTTTGGCGGCGGCACGAAGTTAACCGTTCTTGGC
 CAG,

(b)

GATATCGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGT
 CAGACCGCGCGTATCTCGTGTAGCGGCGATTCTATTGGTAAGAAG
 TATGCTTATTGGTACCAGCAGAAACCCGGGCAGGCGCCAGTTCTT
 GTGATTTATAAGAAGCGTCCCTCAGGCATCCCGGAACGCTTTAGC
 GGATCCAACAGCGGCAACACCGCGACCCTGACCATTAGCGGCACT
 CAGGCGGAAGACGAAGCGGATTATTATTGCTCTGCTTGGGGTGAT
 AAGGGTATGGTGTTTGGCGGCGGCACGAAGTTAACCGTTCTTGGC
 CAG,

10 (c)

GATATCGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGT
 CAGACCGCGCGTATCTCGTGTAGCGGCGATTCTATTGGTAAGAAG
 TATGCTTATTGGTACCAGCAGAAACCCGGGCAGGCGCCAGTTCTT
 GTGATTTATAAGAAGCGTCCCTCAGGCATCCCGGAACGCTTTAGC
 GGATCCAACAGCGGCAACACCGCGACCCTGACCATTAGCGGCACT
 CAGGCGGAAGACGAAGCGGATTATTATTGCTCTGCTTGGGGTGAT
 AAGGGTATGGTGTTTGGCGGCGGCACGAAGTTAACCGTTCTTGGC
 CAG og

(d)

GACATCGAGCTGACCCAGCCCCCAGCGTGTCTGTGGCCCCTGGC
 CAGACCGCCCGGATCAGCTGCTCCGGCGACAGCATCGGCAAGAAG
 TACGCCTACTGGTATCAGCAGAAGCCCGGCCAGGCCCCCGTGCTG
 GTGATCTACAAGAAGCGGCCAGCGGCATCCCCGAGCGGTTCAGC
 GGCAGCAACAGCGGCAACACCGCCACCCTGACCATCAGCGGCACC
 CAGGCCGAGGACGAGGCCGACTACTACTGCTCCGCCTGGGGCGAC
 AAGGGCATGGTGTGTTGGCGGCGGAACAAAGTTAACCGTGCTGGGG
 CAG;

eller

(ii) en nukleinsyresekvens, der under højstringente betingelser hybridiserer til den komplementære streng til sekvensen (i)(a), (i)(b), (i)(c) eller (i)(d).

5

15. Vektor omfattende en nukleinsyresekvens ifølge et hvilket som helst af kravene 12 til 14.

16. Celle omfattende en vektor ifølge krav 15.

10

17. Celle ifølge krav 16, hvilken celle er bakteriel eller eukaryot.

18. Farmaceutisk sammensætning, der omfatter et humant eller humaniseret antistof eller funktionelt fragment deraf ifølge et hvilket som helst af kravene 1 til 11 og et farmaceutisk acceptabelt bærestof eller excipients for dette.

15

19. Farmaceutisk sammensætning ifølge krav 18 til anvendelse ved behandling af en inflammationssygdom.

20. Farmaceutisk sammensætning ifølge krav 19 til anvendelse ifølge krav 19, hvor inflammationssygdommen fremgår af listen arthritis rheumatoides, dissemineret sclerose, Crohn's sygdom, psoriasis, astma og atopisk dermatitis.

20

21. Farmaceutisk sammensætning ifølge krav 19 til anvendelse ifølge krav 19, hvor inflammationssygdommen er arthritis rheumatoides.

25

22. Humant eller humaniseret antistof eller funktionelt fragment deraf ifølge et hvilket som helst af kravene 1 til 11 til anvendelse ved behandling af en inflammationssygdom alene eller i kombination med andre midler.

Figure 1a**Variable Heavy Chain DNA**

3684_VH3 (SEQ ID NO: 1):

CAGGTGCAATTGGTGGAAAGCGGCGGCGGCCTGGTGCAACCGGGCGGCAGCCTGCGTCT
GAGCTGCGCGGCCTCCGGATTTACCTTTTCTTCTCATTGGATGTCTTGGGTGCGCCAAGCC
CCTGGGAAGGGTCTCGAGTGGGTGAGCAATGGTATCTTTCTGATGGTAGCGCTACCTAT
TATGCGGATAGCGTGAAAGGCCGTTTTACCATTTCACGTGATAATTCGAAAAACACCCTG
TATCTGCAAATGAACAGCCTGCGTGCGGAAGATACGGCCGTGTATTATTGCGCGCGTTTT
CAGGGTTATGGTGGTGGTTTTGATTATTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA

4251_VH3 (SEQ ID NO: 2):

CAGGTGCAATTGGTGGAAAGCGGCGGCGGCCTGGTGCAACCGGGCGGCAGCCTGCGTCT
GAGCTGCGCGGCCTCCGGATTTACCTTTTCTTCTCATTGGATGTCTTGGGTGCGCCAAGCC
CCTGGGAAGGGTCTCGAGTGGGTGAGCAATTTGGCGTGGTCCTTATAATTTATTATGCTG
ATTCTGTTAAGGGTCGTTTTACCATTTCACGTGATAATTCGAAAAACACCCTGTATCTGCA
AATGAACAGCCTGCGTGCGGAAGATACGGCCGTGTATTATTGCGCGCGTTTTCAGGGTTA
TGGTGGTGGTTTTGATTATTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA

3929_VH3 (SEQ ID NO: 3):

CAGGTGCAATTGGTGGAAAGCGGCGGCGGCCTGGTGCAACCGGGCGGCAGCCTGCGTCT
GAGCTGCGCGGCCTCCGGATTTACCTTTTCTTCTTATTGGATGAATTGGGTGCGCCAAGCC
CCTGGGAAGGGTCTCGAGTGGGTGAGCGGTATCTCTTATTCTGGTAGCGAGACCTATTAT
GCGGATAGCGTGAAAGGCCGTTTTACCATTTCACGTGATAATTCGAAAAACACCCTGTAT
CTGCAAAATGAACAGCCTGCGTGCGGAAGATACGGCCGTGTATTATTGCGCGCGTGGTTTT
GGTACTGATTTTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA

4252_VH 3 (SEQ ID NO: 4):

CAGGTGCAATTGGTGGAAAGCGGCGGCGGCCTGGTGCAACCGGGCGGCAGCCTGCGTCT
GAGCTGCGCGGCCTCCGGATTTACCTTTTCTTCTTATTGGATGAATTGGGTGCGCCAAGCC
CCTGGGAAGGGTCTCGAGTGGGTGAGCGGTATTGAGAATAAGTATGCTGGTGGTGTACT
TATTATGCTGCTTCTGTTAAGGGTCGTTTTACCATTTCACGTGATAATTCGAAAAACACCC
TGTATCTGCAAATGAACAGCCTGCGTGCGGAAGATACGGCCGTGTATTATTGCGCGCGTG
GTTTTGGTACTGATTTTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA

4287_VH3 (SEQ ID NO: 5):

CAGGTGCAATTGGTGGAAAGCGGCGGCGGCCTGGTGCAACCGGGCGGCAGCCTGCGTCT
GAGCTGCGCGGCCTCCGGATTTACCTTTTCTTCTTATTGGATGAATTGGGTGCGCCAAGCC
CCTGGGAAGGGTCTCGAGTGGGTGAGCGGTATTGAGAATAAGCGTGCTGGTGGTGTACT
TTTTATGCTGCTTCCGTTAAGGGTCGTTTTACCATTTCACGTGATAATTCGAAAAACACCC
TGTATCTGCAAATGAACAGCCTGCGTGCGGAAGATACGGCCGTGTATTATTGCGCGCGTG
GTTTTGGTACTGATTTTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA

4290_VH3 (SEQ ID NO: 6):

CAGGTGCAATTGGTGGAAAGCGGCGGCGGCCTGGTGCAACCGGGCGGCAGCCTGCGTCT
GAGCTGCGCGGCCTCCGGATTTACCTTTTCTTCTTATTGGATGAATTGGGTGCGCCAAGCC
CCTGGGAAGGGTCTCGAGTGGGTGAGCGGTATTGAGTCTAAGTGGGCTGGTGGTGTACT
TATTATGCTGCTGGTGTAAAGGGTCGTTTTACCATTTCACGTGATAATTCGAAAAACACCC
TGTATCTGCAAATGAACAGCCTGCGTGCGGAAGATACGGCCGTGTATTATTGCGCGCGTG
GTTTTGGTACTGATTTTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA

4302_VH3 (SEQ ID NO: 7):

CAGGTGCAATTGGTGGAAAGCGGCGGCGGCCTGGTGCAACCGGGCGGCAGCCTGCGTCT
GAGCTGCGCGGCCTCCGGATTTACCTTTTCTTCTTATTGGATGAATTGGGTGCGCCAAGCC
CCTGGGAAGGGTCTCGAGTGGGTGAGCGGTATCTCTTATTCTGGTAGCGAGACCTATTAT
GCGGATAGCGTGAAAGGCCGTTTTACCATTTACGTGATAATTCGAAAAACACCCTGTAT
CTGCAAATGAACAGCCTGCGTGCGGAAGATACGGCCGTGTATTATTGCGCGCGTGGTTTT
GGTACTGATTTTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA

4350_VH3 (SEQ ID NO: 8):

CAGGTGCAATTGGTGGAAAGCGGCGGCGGCCTGGTGCAACCGGGCGGCAGCCTGCGTCT
GAGCTGCGCGGCCTCCGGATTTACCTTTTCTTCTTATTGGATGAATTGGGTGCGCCAAGCC
CCTGGGAAGGGTCTCGAGTGGGTGAGCGGTATTGAGAATAAGCGTGCTGGTGGTGCTACT
TTTTATGCTGCTTCCGTTAAGGGTCGTTTTACCATTTACGTGATAATTCGAAAAACACCC
TGTATCTGCAAATGAACAGCCTGCGTGCGGAAGATACGGCCGTGTATTATTGCGCGCGTG
GTTTTGGTACTGATTTTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA

4354_VH3 (SEQ ID NO: 9):

CAGGTGCAATTGGTGGAAAGCGGCGGCGGCCTGGTGCAACCGGGCGGCAGCCTGCGTCT
GAGCTGCGCGGCCTCCGGATTTACCTTTTCTTCTTATTGGATGAATTGGGTGCGCCAAGCC
CCTGGGAAGGGTCTCGAGTGGGTGAGCGGTATTGAGTCTAAGTGGGCTGGTGGTGCTACT
TATTATGCTGCTGGTGTTAAGGGTCGTTTTACCATTTACGTGATAATTCGAAAAACACCC
TGTATCTGCAAATGAACAGCCTGCGTGCGGAAGATACGGCCGTGTATTATTGCGCGCGTG
GTTTTGGTACTGATTTTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA

4357_VH3 (SEQ ID NO: 10):

CAGGTGCAATTGGTGGAAAGCGGCGGCGCCTGGTGCAACCGGGCGGCAGCCTGCGTCT
GAGCTGCGCGGCCTCCGGATTTACCTTTTCTTCTTATTGGATGAATTGGGTGCGCCAAGCC
CCTGGGAAGGGTCTCGAGTGGGTGAGCGGTATTGAGAATAAGTATGCTGGTGGTGTACT
TATTATGCTGCTTCTGTTAAGGGTCGTTTTACCATTTACGTGATAATTCGAAAAACCCC
TGTATCTGCAAATGAACAGCCTGCGTGCGGAAGATACGGCCGTGTATTATTGCGCGCGTG
GTTTTGGTACTGATTTTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA

3682_VH1A (SEQ ID NO: 44)

CAGGTGCAATTGGTTCAGTCTGGCGCGGAAGTGAAAAACCGGGCAGCAGCGTG
AAAGTGAGCTGCAAAGCCTCCGGAGGCACTTTTAATTCTTTTCTTATTTCTTGGGT
GCGCCAAGCCCCTGGGCAGGGTCTCGAGTGGATGGGCGGTATCATTCCGATTTTT
GGCACTGCGAATTACGCGCAGAAGTTTCAGGGCCGGGTGACCATTACCGCGGATG
AAAGCACCAGCACCGGTATATGGAAGTGAAGCAGCCTGCGTAGCGAAGATACGG
CCGTGTATTATTGCGCGCGTAAGTTTATTTCTGATTCTTGGGGCCAAGGCACCCTG
GTGACGGTTAGCTCA

4283_VH1A (SEQ ID NO: 45)

CAGGTGCAATTGGTTCAGTCTGGCGCGGAAGTGAAAAACCGGGCAGCAGCGTG
AAAGTGAGCTGCAAAGCCTCCGGAGGCACTTTTAATTCTTTTCTTATTTCTTGGGT
GCGCCAAGCCCCTGGGCAGGGTCTCGAGTGGATGGGCGCTATTTCTCCTTGGGAT
GGTGTTACTGGTTATGCTCAGAAGTTTCAGGGTTCGGGTGACCATTACCGCGGATG
AAAGCACCAGCACCGGTATATGGAAGTGAAGCAGCCTGCGTAGCGAAGATACGG
CCGTGTATTATTGCGCGCGTAAGTTTATTTCTGATTCTTGGGGCCAAGGCACCCTG
GTGACGGTTAGCTCA

4297_VH1A (SEQ ID NO: 46)

CAGGTGCAATTGGTTCAGTCTGGCGCGGAAGTGAAAAAACCGGGCAGCAGCGTG
AAAGTGAGCTGCAAAGCCTCCGGAGGCACTTTTAATTCTTTTCTTATTTCTTGGGT
GCGCCAAGCCCCTGGGCAGGGTCTCGAGTGGATGGGCGGTATCATTCCGATTTTT
GGCACTGCGAATTACGCGCAGAAGTTTCAGGGCCGGGTGACCATTACCGCGGATG
AAAGCACCAGCACCGCGTATATGGAAGTCTGAGCAGCCTGCGTAGCGAAGATACGG
CCGTGTATTATTGCGCGCGTAAGTTTATTTCTGATTCTTGGGGCCAAGGCACCCTG
GTGACGGTTAGCTCA

4342_VH1A (SEQ ID NO: 47)

CAGGTGCAATTGGTTCAGTCTGGCGCGGAAGTGAAAAAACCGGGCAGCAGCGTG
AAAGTGAGCTGCAAAGCCTCCGGAGGCACTTTTAATTCTTTTCTTATTTCTTGGGT
GCGCCAAGCCCCTGGGCAGGGTCTCGAGTGGATGGGCGCTATTTCTCCTTGGGAT
GGTGTACTGGTTATGCTCAGAAGTTTCAGGGTCTGGGTGACCATTACCGCGGATG
AAAGCACCAGCACCGCGTATATGGAAGTCTGAGCAGCCTGCGTAGCGAAGATACGG
CCGTGTATTATTGCGCGCGTAAGTTTATTTCTGATTCTTGGGGCCAAGGCACCCTG
GTGACGGTTAGCTCA

4357_VH codon-optimized (SEQ ID NO: 48)

CAGGTGCAGCTGGTTCGAGTCTGGCGGCGGACTGGTGCAGCCTGGCGGCAGCCTG
AGACTGAGCTGTGCCGCCAGCGGCTTCACCTTCAGCAGCTACTGGATGAACTGGG
TGAGGCAGGCCCTGGCAAGGGCCTGGAGTGGGTGTCCGGCATCGAGAACAAGT
ATGCCGGCGGAGCCACCTACTACGCCGCCAGCGTGAAGGGCCGGTTCACCATCAG
CCGGGACAACAGCAAGAACCCTGTACCTGCAGATGAACAGCCTGAGGGCCGA
GGACACCGCCGTGTACTACTGTGCCAGGGGCTTCGGCACCGATTTCTGGGGCCAG
GGCACCCCTGGTGACAGTCAGCTCA

Figure 1b

Variable Heavy Chain Peptide
(CDR Regions in Bold)

3684_VH3 (SEQ ID NO: 11):

QVQLVESGGGLVQPGGSLRLS**CAASGFTFSSHWMSWVRQAPGKGLEWVSN**GI**FS**DGSATY
YADSVKGRFTISRDN**SKNTLYLQMN**SLRAEDTAVYYC**ARFQGYGGG**FDYWGQGT**LVTVSS**

4251_VH3 (SEQ ID NO: 12):

QVQLVESGGGLVQPGGSLRLS**CAASGFTFSSHWMSWVRQAPGKGLEWVSN**IWRGPYIYYA
DSVKGRFTISRDN**SKNTLYLQMN**SLRAEDTAVYYC**ARFQGYGGG**FDYWGQGT**LVTVSS**

3929_VH3 (SEQ ID NO: 13):

QVQLVESGGGLVQPGGSLRLS**CAASGFTFSSYWMNWVRQAPGKGLEWVSG**ISYSG**SETYY**
ADSVKGRFTISRDN**SKNTLYLQMN**SLRAEDTAVYYC**ARGFGTDF**WGQGT**LVTVSS**

4252_VH3 (SEQ ID NO: 14):

QVQLVESGGGLVQPGGSLRLS**CAASGFTFSSYWMNWVRQAPGKGLEWVSG**IENKYAGGA
TYAASVKGRFTISRDN**SKNTLYLQMN**SLRAEDTAVYYC**ARGFGTDF**WGQGT**LVTVSS**

4287_VH3 (SEQ ID NO: 15):

QVQLVESGGGLVQPGGSLRLS**CAASGFTFSSYWMNWVRQAPGKGLEWVSG**IENKRAGGA
TFYAASVKGRFTISRDN**SKNTLYLQMN**SLRAEDTAVYYC**ARGFGTDF**WGQGT**LVTVSS**

4290_VH 3 (SEQ ID NO: 16):

QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSGIESKWAGGA
TYAAAGVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARGFGTDFWGGQGLVTVSS

4302_VH 3 (SEQ ID NO: 17):

QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSGISYSGSETYY
ADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARGFGTDFWGGQGLVTVSS

4350_VH 3 (SEQ ID NO: 18):

QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSGIENKRAGGA
TFYAASVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARGFGTDFWGGQGLVTVSS

4354_VH 3 (SEQ ID NO: 19):

QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSGIESKWAGGA
TYAAAGVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARGFGTDFWGGQGLVTVSS

4357_VH 3 (SEQ ID NO: 20):

QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSGIENKYAGGA
TYAASVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARGFGTDFWGGQGLVTVSS

3682_VH1A (SEQ ID NO: 49)

QVQLVQSGAEVKKPGSSVKV SCKASGGTFNSFLISWVRQAPGQGLEWMGGIPIFG
TANYAQKFQGRVTITADESTSTAYMELSSLRSED TAVYYCARKFISDSWGQGLVTV
SS

4283_VH1A (SEQ ID NO: 50)

QVQLVQSGAEVKKPGSSVKV SCKASGGTFNSFLISWVRQAPGQGLEWMGAISPWD
GVTGYAQKFQGRVTITADESTSTAYMELSSLRSEDTA VYYCARKFISDSWGQGLV
TVSS

4297_VH1A (SEQ ID NO: 51)

QVQLVQSGAEVKKPGSSVKV SCKASGGTFNSFLISWVRQAPGQGLEWMGGIPIFG
TANYAQKFQGRVTITADESTSTAYMELSSLRSEDTA VYYCARKFISDSWGQGLVTV
SS

4342_VH1A (SEQ ID NO: 52)

QVQLVQSGAEVKKPGSSVKV SCKASGGTFNSFLISWVRQAPGQGLEWMGAISPWD
GVTGYAQKFQGRVTITADESTSTAYMELSSLRSEDTA VYYCARKFISDSWGQGLV
TVSS

Figure 2a

Variable Light Chain DNA

3684_VL lambda 3 (SEQ ID NO: 21):

GATATCGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGTCAGACCGCGCGTATC
TCGTGTAGCGGCGATAATCTTCCTGGTAAGTATGTTTCATTGGTACCAGCAGAAACCCGGG
CAGGCGCCAGTTCTTGTGATTTATTATGATTCTAATCGTCCCTCAGGCATCCCGGAACGCT
TTAGCGGATCCAACAGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAA
GACGAAGCGGATTATTATTGCCAGTCTCGTACTCAGACTACTATTGTGTTTGGCGGCGGC
ACGAAGTTAACCGTTCTTGGCCAG

4251_VL lambda 3 (SEQ ID NO: 22):

GATATCGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGTCAGACCGCGCGTATC
TCGTGTAGCGGCGATAATCTTCCTGGTAAGTATGTTTCATTGGTACCAGCAGAAACCCGGG
CAGGCGCCAGTTCTTGTGATTTATTATGATTCTAATCGTCCCTCAGGCATCCCGGAACGCT
TTAGCGGATCCAACAGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAA
GACGAAGCGGATTATTATTGCCAGTCTCGTACTCAGACTACTATTGTGTTTGGCGGCGGC
ACGAAGTTAACCGTTCTTGGCCAG

3929_VL lambda 3 (SEQ ID NO: 23):

GATATCGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGTCAGACCGCGCGTATC
TCGTGTAGCGGCGATTCTATTGGTAAGAAGTATGCTTATTGGTACCAGCAGAAACCCGGG
CAGGCGCCAGTTCTTGTGATTTATAAGAAGCGTCCCTCAGGCATCCCGGAACGCTTTAGC
GGATCCAACAGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAAGACGA
AGCGGATTATTATTGCTCTTCTTGGGATTCTACTGGTCTTGTGTTTGGCGGCGGCACGAAG
TTAACCGTTCTTGGCCAG

4252_VL lambda 3 (SEQ ID NO: 24):

GATATCGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGTCAGACCGCGCGTATC
TCGTGTAGCGGCGATTCTATTGGTAAGAAGTATGCTTATTGGTACCAGCAGAAACCCGGG
CAGGCGCCAGTTCTTGTGATTTATAAGAAGCGTCCCTCAGGCATCCCGGAACGCTTTAGC
GGATCCAACAGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGA
AGCGGATTATTATTGCTCTTCTTGGGATTCTACTGGTCTTGTGTTTGGCGGCGGCACGAAG
TTAACCGTTCTTGGCCAG

4287_VL lambda 3 (SEQ ID NO: 25):

GATATCGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGTCAGACCGCGCGTATC
TCGTGTAGCGGCGATTCTATTGGTAAGAAGTATGCTTATTGGTACCAGCAGAAACCCGGG
CAGGCGCCAGTTCTTGTGATTTATAAGAAGCGTCCCTCAGGCATCCCGGAACGCTTTAGC
GGATCCAACAGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGA
AGCGGATTATTATTGCTCTTCTTGGGATTCTACTGGTCTTGTGTTTGGCGGCGGCACGAAG
TTAACCGTTCTTGGCCAG

4290_VL lambda 3 (SEQ ID NO: 26):

GATATCGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGTCAGACCGCGCGTATC
TCGTGTAGCGGCGATTCTATTGGTAAGAAGTATGCTTATTGGTACCAGCAGAAACCCGGG
CAGGCGCCAGTTCTTGTGATTTATAAGAAGCGTCCCTCAGGCATCCCGGAACGCTTTAGC
GGATCCAACAGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGA
AGCGGATTATTATTGCTCTTCTTGGGATTCTACTGGTCTTGTGTTTGGCGGCGGCACGAAG
TTAACCGTTCTTGGCCAG

4302_VL lambda 3 (SEQ ID NO: 27):

GATATCGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGTCAGACCCGCGCGTATC
TCGTGTAGCGGCGATTCTATTGGTAAGAAGTATGCTTATTGGTACCAGCAGAAACCCGGG
CAGGCGCCAGTTCTTGTGATTTATAAGAAGCGTCCCTCAGGCATCCCGGAACGCTTTAGC
GGATCCAACAGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGA
AGCGGATTATTATTGCTCTGCTTGGGGTGATAAGGGTATGGTGTTTGGCGGCGGCACGAA
GTAAACCGTTCTTGGCCAG

4350_VL lambda 3 (SEQ ID NO: 28):

GATATCGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGTCAGACCCGCGCGTATC
TCGTGTAGCGGCGATTCTATTGGTAAGAAGTATGCTTATTGGTACCAGCAGAAACCCGGG
CAGGCGCCAGTTCTTGTGATTTATAAGAAGCGTCCCTCAGGCATCCCGGAACGCTTTAGC
GGATCCAACAGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGA
AGCGGATTATTATTGCTCTGCTTGGGGTGATAAGGGTATGGTGTTTGGCGGCGGCACGAA
GTAAACCGTTCTTGGCCAG

4354_VL lambda 3 (SEQ ID NO: 29):

GATATCGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGTCAGACCCGCGCGTATC
TCGTGTAGCGGCGATTCTATTGGTAAGAAGTATGCTTATTGGTACCAGCAGAAACCCGGG
CAGGCGCCAGTTCTTGTGATTTATAAGAAGCGTCCCTCAGGCATCCCGGAACGCTTTAGC
GGATCCAACAGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGA
AGCGGATTATTATTGCTCTGCTTGGGGTGATAAGGGTATGGTGTTTGGCGGCGGCACGAA
GTAAACCGTTCTTGGCCAG

4357_VL lambda 3 (SEQ ID NO: 30):

GATATCGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGTCAGACCGCGCGTATC
TCGTGTAGCGGCGATTCTATTGGTAAGAAGTATGCTTATTGGTACCAGCAGAAACCCGGG
CAGGCGCCAGTTCTTGTGATTTATAAGAAGCGTCCCTCAGGCATCCCGGAACGCTTTAGC
GGATCCAACAGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGA
AGCGGATTATTATTGCTCTGCTTGGGGTGATAAGGGTATGGTGTGGCGGCGGCACGAA
GTTAACCGTTCTTGGCCAG

3682_VL kappa 1 (SEQ ID NO: 53)

GATATCCAGATGACCCAGAGCCCGTCTAGCCTGAGCGCGAGCGTGGGTGATCGTG
TGACCATTACCTGCAGAGCGAGCCAGACTATTAATAATTATCTGAATTGGTACCA
GCAGAAACCAGGTAAAGCACCGAAACTATTAATTTATACTGCTTCTAATTTGCAA
AGCGGGGTCCCGTCCCGTTTTAGCGGCTCTGGATCCGGCACTGATTTTACCCTGAC
CATTAGCAGCCTGCAACCTGAAGACTTTGCGGTTTATTATTGCCAGCAGTATTCTG
GTTCTCCTATGACCTTTGGCCAGGGTACGAAAGTTGAAATTAACGTACG

4283_VL kappa 1 (SEQ ID NO: 54)

GATATCCAGATGACCCAGAGCCCGTCTAGCCTGAGCGCGAGCGTGGGTGATCGTG
TGACCATTACCTGCAGAGCGAGCCAGACTATTAATAATTATCTGAATTGGTACCA
GCAGAAACCAGGTAAAGCACCGAAACTATTAATTTATACTGCTTCTAATTTGCAA
AGCGGGGTCCCGTCCCGTTTTAGCGGCTCTGGATCCGGCACTGATTTTACCCTGAC
CATTAGCAGCCTGCAACCTGAAGACTTTGCGGTTTATTATTGCCAGCAGTATTCTG
GTTCTCCTATGACCTTTGGCCAGGGTACGAAAGTTGAAATTAACGTACG

4297_VL kappa 1 (SEQ ID NO: 55)

GATATCCAGATGACCCAGAGCCCGTCTAGCCTGAGCGCGAGCGTGGGTGATCGTG
TGACCATTACCTGCAGAGCGAGCCAGACTATTAATAATTATCTGAATTGGTACCA

GCAGAAACCAGGTAAAGCACCGAAACTATTAATTTATACTGCTTCTAATTTGCAA
AGCGGGGTCCCGTCCCGTTTTAGCGGCTCTGGATCCGGCACTGATTTTACCCTGAC
CATTAGCAGCCTGCAACCTGAAGACTTTGCGACCTATTATTGCCAGCAGTATTCTT
GGGTTCCCTCATACTTTGGCCAGGGTACGAAAGTTGAAATTAACGTACG

4342_VL kappa 1 (SEQ ID NO: 56)

GATATCCAGATGACCCAGAGCCCGTCTAGCCTGAGCGCGAGCGTGGGTGATCGTG
TGACCATTACCTGCAGAGCGAGCCAGACTATTAATAATTATCTGAATTGGTACCA
GCAGAAACCAGGTAAAGCACCGAAACTATTAATTTATACTGCTTCTAATTTGCAA
AGCGGGGTCCCGTCCCGTTTTAGCGGCTCTGGATCCGGCACTGATTTTACCCTGAC
CATTAGCAGCCTGCAACCTGAAGACTTTGCGACCTATTATTGCCAGCAGTATTCTT
GGGTTCCCTCATACTTTGGCCAGGGTACGAAAGTTGAAATTAACGTACG

4357_VL codon-optimized (SEQ ID NO: 57)

GACATCGAGCTGACCCAGCCCCCAGCGTGTCTGTGGCCCCTGGCCAGACCGCCC
GGATCAGCTGCTCCGGCGACAGCATCGGCAAGAAGTACGCCTACTGGTATCAGCA
GAAGCCCGGCCAGGCCCCCGTGCTGGTGATCTACAAGAAGCGGCCAGCGGCAT
CCCCGAGCGGTTCAAGCGGCAGCAACAGCGGCAACACCGCCACCCTGACCATCAG
CGGCACCCAGGCCGAGGACGAGGCCGACTACTACTGCTCCGCCTGGGGCGACAA
GGGCATGGTGTGTTGGCGGCGGAACAAAGTTAACCGTGCTGGGGCAG

Figure 2b**Variable Light Chain Peptide**
(CDR Regions in **Bold**)

3684_ VL lambda 3 (SEQ ID NO: 31):

DIELTQPPSVSVAPGQTARISCSG**DNLP**GKYVHWYQKPGQAPVLVIYYDSNRPSGIPERFSG
SNSGNTATLTISGTQAED**EADYYCQ**SRT**QTTIV**FGGGTKLTVLGQ

4251_ VL lambda 3 (SEQ ID NO: 32):

DIELTQPPSVSVAPGQTARISCSG**DNLP**GKYVHWYQKPGQAPVLVIYYDSNRPSGIPERFSG
SNSGNTATLTISGTQAED**EADYYCQ**SRT**QTTIV**FGGGTKLTVLGQ

3929_ VL lambda 3 (SEQ ID NO: 33):

DIELTQPPSVSVAPGQTARISCSG**DSIG**KKYAYWYQKPGQAPVLVIYKKRPSGIPERFSGS**NS**
GNTATLTISGTQAED**EADYYC**SSWDSTGLVFGGGTKLTVLGQ

4252_ VL lambda 3 (SEQ ID NO: 34):

DIELTQPPSVSVAPGQTARISCSG**DSIG**KKYAYWYQKPGQAPVLVIYKKRPSGIPERFSGS**NS**
GNTATLTISGTQAED**EADYYC**SSWDSTGLVFGGGTKLTVLGQ

4287_ VL lambda 3 (SEQ ID NO: 35):

DIELTQPPSVSVAPGQTARISCSG**DSIG**KKYAYWYQKPGQAPVLVIYKKRPSGIPERFSGS**NS**
GNTATLTISGTQAED**EADYYC**SSWDSTGLVFGGGTKLTVLGQ

4290_VL lambda 3 (SEQ ID NO: 36):

DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKRPSGIPERFSGSNS
GNTATLTISGTQAEDEADYYCSSWDSTGLVFGGGTKLTVLGQ

4302_VL lambda 3 (SEQ ID NO: 37):

DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKRPSGIPERFSGSNS
GNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTKLTVLGQ

4350_VL lambda 3 (SEQ ID NO: 38):

DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKRPSGIPERFSGSNS
GNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTKLTVLGQ

4354_VL lambda 3 (SEQ ID NO: 39):

DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKRPSGIPERFSGSNS
GNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTKLTVLGQ

4357_VL lambda 3 (SEQ ID NO: 40):

DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKRPSGIPERFSGSNS
GNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTKLTVLGQ

3682_VL kappa 1 (SEQ ID NO: 58)

DIQMTQSPSSLSASVGDRVTITCRASQTINNYLNWYQQKPGKAPKLLIYTASNLSGVPSRFS
GSGSGTDFLTISLQPEDFAVYYCQYSGSPMTFGQGTKVEIKRT

4283_VL kappa 1 (SEQ ID NO: 59)

DIQMTQSPSSLSASVGDRVITTCRASQTINNYLNWYQQKPGKAPKLLIYTASNLSQGVPSRFS
GSGSGTDFLTISLQPEDFAVYYCQQYSGSPMTFGQGTKVEIKRT

4297_VL kappa 1 (SEQ ID NO: 60)

DIQMTQSPSSLSASVGDRVITTCRASQTINNYLNWYQQKPGKAPKLLIYTASNLSQGVPSRFS
GSGSGTDFLTISLQPEDFATYYCQQYSWVPHTFGQGTKVEIKRT

4342_VL kappa 1 (SEQ ID NO: 61)

DIQMTQSPSSLSASVGDRVITTCRASQTINNYLNWYQQKPGKAPKLLIYTASNLSQGVPSRFS
GSGSGTDFLTISLQPEDFATYYCQQYSWVPHTFGQGTKVEIKRT

Figure 3

**Variable Heavy Chain Consensus Sequence
(CDR Regions in Bold)**

VH3 Consensus (SEQ ID NO: 41):

QVQLVESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSA
ISGSGGSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARWG
GDGFYAMDYW GQGLVTVS S

Figure 4

Variable Light Chain Consensus Sequence
(CDR Regions in **Bold**)

VL_{λ3} Consensus (SEQ ID NO: 42):

DIELTQPPSV SVAPGQTARI SCSGDALGDK **YASWYQQKPG QAPVLVIYDD**
SDRPSGIPER FSGSNSGNTA TLTISGTQAE DEADYYCQQH YTTPPVFGGG
TKLTVLG

Figure 5

Example of DNA sequence of Fab expression vector pMORPH[®]X9_MOR03929_FH
SEQ ID NO: 43

atgaaaaagacagctatcgcgattgcagtggcactggctggttcgtaccgtagcgcagg-
ccgatatcgaactgacctagccgcttcagtgagcgttcaccagggtcagaccgcgcgtat-
ctcgtgtagcggcgattctattggttaagaagtatgcttattggtaccagcagaaaccggg-
caggcggcagttctgtgattataagaagcgtccctcaggcatcccggaacgcttagcg-
gatccaacagcggcaacaccgcgacctgaccattagcggcactcaggcgggaagacgaag-
cggattatttctcttcttgggattctactggcttctgtttggcggcggcacgaagt-
taaccgttcttggccagccgaaagccgaccgagtgtagcgtgttccgccgagcag-
cgaagaattgcaggcgaacaaagcgacctgggtgctgattagcgactttatccgg-
gagccgtgacagtgccctggaaggcagatagcagccccgtcaaggcgggagtgaggaccac-
cacacctccaacaaagcaacaacaagtacggccagcagctatctgagcctgacgcct-
gagcagtggaagtccacagaagctacagctgccaggtcacgcatgaggggagcaccgtg-
gaaaaaccgtgcccactgaggcctgataagcatcgtaggagaaaataaaatgaaa-
caaaactacttgcactggcactctaccgttctcttcacctgttaccaaagcccagg-
tgcaattggtgaaagcggcggcgccctgggtgcaaccggcggcagcctgctctgagctg-
cgcgccctccgattacctttctcttattggatgaattgggtgcgccaagcccctgg-
gaagggtctcgagtggtgagcggatctcttattctggtagcgagacctattatcggga-
tagcgtgaaaggccgttttaccattcacgtgataattcgaacaccctgtatctg-
caaatgaacagcctgcgtgcggaagatacggccgtgtattatgcgcgcgtggtttgg-
tactgattttggggccaaggcaccctggtagcggtagctcagcgtcgaccaaaggtc-
caagcgtgttccgctggctccgagcagcaaaagcaccagcggcggcacggctgccctggg-
ctgccctggttaaagattttcccggaaccagtcaccgtgagctggaacagcggggcgct-
gaccagcggcgtgatacctttccggcggtgctgcaaagcagcggcctgtatagcctgag-
cagcgtgtgaccgtgccgagcagcagcttaggcactcagacctatattgcaacgtgaac-
cataaacgagcaacaccaaagtggataaaaaagtggaaccgaaaagcgaattcgacta-
taaagatgacgatgacaaaggcgcgccgaccatcatcaccatcactgataagcttgacc-
tgtgaagtgaaaaaatggcgcagattgtcgcacattttttgtctgccgttaataaagg-
ggggggggggcggcctgggggggggtgtacatgaaattgaaacgttaataattttgt-
taaaatcgcgttaattttgttaaacagctcatttttaaccaataggccgaaatcgg-
caaaatccctataaatcaaaagaatagaccgagatagggttagtgttggcagttg-
gaacaagagtcactattaagaacgtggactccaacgtcaaaaggcgaaaaaccgtctat-
caggggcgtgcccactacgagaacctaccctaataagttttggggcagaggtgc-
cgtaaagcactaaatcggaaccctaaggaggcggcggcggcggcgttagggcgctgg-
cggcgaacgtggcgagaaaggaagggaagaaagcgaaggagcggcgcttagggcgctgg-
caagtglagcgggtcacgctgcgcgtaaccaccacaccgccgcgcttaatgcgccgta-
caggcgcgtgctagactagtgttaaacggaccggggggggccttaagtgggctg-
caaaacaaaacggcctctgtcaggaagccgtttatcgggtagcctcactgcccgttt-
ccagtcgggaaacctgtgtgccagctgcatcagtgatcggccaacgcgcggggagagg-
cggtttgcgtattgggagccaggggtgtttttcaccagtgagacgggcaacagct-
gattgccctcaccgctggccctgagagagttgcagcaagcggtcacgctggtttgcc-
cagcaggcgaaaaatcctgtttgatggtggtcagcggcgggataaacatgagctgtcct-
cggtatcgtcgtatcccactaccgagatgtccgaccaaacgcgcagcccggactcggtaat-
ggcacgcattgcgccagcggcctatgatcgttggcaaccagcagcagtggaacgatg-
ccctcattcagcattgcatggttgtgaaaaccggacatggcactccagtcgccttcc-

cgticcgciatcggctgaatttgattgcgagtgagatattatgccagccagccagacg-
cagacgcgccgagacagaacttaatgggccagctaacagcgcgatttgctggggcccaat-
gcgaccagatgctccacgccagtcgctaccgtcctcatgggagaaaataactgtt-
gatgggtgctggctcagagacatcaagaaataacgccggaacattagtcaggcagcttc-
cacagcaatagcatcctggctatccagcggatagtaataatcagcccactgacacgttg-
cgcgagaagattgtgcaccgccgcttacaggcttcgacgccgcttcgttctaccatcga-
cacgaccacgctggcaccagttgatcggcgcgagattaatcgccgcgacaattg-
cgacggcgcgtgcagggccagactggaggtggcaacgccaatcagcaacgactgttggc-
cgccagttgttgccacgcggttaggaatgtaattcagctccgccatcgccgcttcac-
ttttccgcgcttgcagaaacgtggctggcctgggtcaccacgcgggaaacggctgta-
taagagacaccggcatactctgcgacatcgtataacgttactggttcacattaccacc-
tgaattgactctctccgggcgtatcatgccataaccgcgaaagggtttgcccattcga-
gctagccatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaggccgcgtgctg-
gctgtttccataggctccgccccctgacgagcatcaaaaaatcagcgtcaagt-
cagaggtggcgaaacccgacaggactataaagataaccagggcttccccctggaagctccc-
tcgtgctctcctgttccgacctgcccgttaccggatacctgctccgcttctccctt-
cgggaagcgtggcgttctcatagctcacgctgtaggtatctcagttcgggtgtaggtcg-
ttcgtccaagctggcgtgtgtgcacgaacccccgttcagcccagccgctgcgcttacc-
cggttaactatgctttagtccaacccggtaagacacgactatcggcactggcagcagc-
cactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttcttgaagtgg-
tgccctaactacggctacactagaagaacagatattggtatctgcgctctgctgtagccag-
ttacctcggaaaaagagttggtagctcttgatcggcaacaaccaccgctggtagcgg-
tggtttttgttgcaagcagcagattacgcgcagaaaaaaggatcicaagaagatcc-
tttgatctttctacggggtcagcgtcagtggaacgaaaactcacgttaagggtttt-
ggtcagatctagcaccagcgttaagggcaccaataactgccttaaaaaattacgcc-
cgccctgccactcatcgcagttactgttgaattcattaagcattctgccgacatggaagc-
catcacaacggcatgatgaacctgaatcggcagcggcatcagcacctgtcgccttgcg-
tataatattgccatagtgaaaacggggcgaaaggtgtccatattggctacgtt-
taaatcaaaactggtgaaactcaccagggattggctgagacgaaaaacatatttcaa-
taaaccttttagggaaataggccaggtttcaccgtaacacgccacatcttgcgaata-
tatgttagaaactgccggaatcgtcgtggtattcactccagagc gatgaaaacgttt-
cagtttgcctatggaaaacgggtgaacaagggtgaacactatccatataccagctcac-
cgtcttctcattgccatacggaaactccgggtgagcattcatcagcgggcaagaatgtgaa-
taaggcggataaaaactgtgcttattttcttacggctttaaaggccgtaatac-
cagctgaacggcttggttataggtacattgagcaactgactgaaatgcctcaaaatgttc-
ttacgatgccattgggatatacaacgggtggtatataccagtgattttttctccattt-
tagcttccctagctcctgaaaaactcgataactcaaaaaatacggcggtagtgatct-
tatttcattatggtgaaagttggaacctcaccgacgtctaattgtgagttagctcactcat-
taggcaccccaggcttacactttatgcttccggctcgtatgttgggaattgtgagcg-
gataacaatttcacacaggaacagctatgaccatgattacgaatttctagataacgagggcaaaaa

Figure 6

